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Antibiotic resistance in human periodontitis  
























top: Photograph of human mandibular lateral incisor tooth, and radiograph of mandibular 
endosseous root form dental implant. 
 
lower left: Photograph in 1928 of first in vitro antibiotic resistance testing on culture plate 
leading to initial discovery of first antibiotic, penicillin, by Sir Alexander Fleming. Note 
zone of staphylococcal growth inhibition between penicillin-producing mold colonies at 
top, and uninhibited staphylococcal colonies on bottom. Published in Fleming, A. (1929) 
On the antibacterial action of cultures of a penicillium with special reference to their use in 
the isolation of B. influenae. British Journal of Experimental Pathology 10: 226-236.      
 
lower right: Photograph 85 years later in 2013 of in vitro antibiotic resistance testing of a 
Prevotella intermedia/nigrescens strain isolated from the subgingival microbiota of a 
chronic periodontitis patient. Note antibiotic-resistant P. intermedia/nigrescens colonies 
exhibiting uninhibited growth on enriched Brucella blood agar in presence of clindamycin 
released from E-test strip (numbers indicate mg/L of clindamycin eluted from segment of 
E-test strip). 
 
Back: Anaerobically-incubated culture colonies of polymicrobial subgingival microbiota 
characteristic of human periodontitis and peri-implantitis.  
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           Pioneered anti-infective non-surgical periodontal therapy starting in the mid-1970s. 
 
Arrest of periodontal lesions will become more predictable as clinicians modulate 
therapeutic measures until periodontopathic microorganisms have been brought 
under control (1). 
 
Successful management of periodontal diseases will depend upon recognition 
of the microbiological targets that need to be eliminated to arrest and prevent 
periodontitis, and on the proper [microbiological] monitoring and modulation  
of whatever type of therapy is selected to control creviculoradicular infections (2).   
 
The end point of our [periodontal] therapy is conversion from disease-associated 
bacterial complexes to health-associated populations. It is increasingly important 
that clinicians tell patients whether they are in the safety zone microbiologically  
and whether they are free of bacterial risk factors associated with destructive 
periodontitis (3). 
 
1.  Keyes, P.H. (1985) Microbiologically monitored and modulated periodontal  
     therapy. General Dentistry 33:105-113. 
 
2.  Keyes, P.H. (1984) A treatment rationale for management of periodontal  
     diseases. Journal of the Alabama Dental Association 68(1):18-25. 
 
3.  Keyes, P.H. (1982) Microbiologically modulated periodontal therapeutics: 
     an introduction. Quintessence International 12: 1321-1325. 
 
 
Paranimfen:  Patrick Rurenga  
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The use of microbiological diagnostics to help guide treatment of human bacterial 
infections dates back to the second decade of the 20th century during World War I.  
According to Edberg (1), French surgeons used quantitative microbiological findings to 
assist in their management of traumatic war wounds in French troops as follows: 
 
A wounded soldier is carried to an aid station from the trenches of France – the year is 
1917. His uniform is cut away and, if the wound is greater than 15 hours old, a wide 
debridement is performed. Disinfectant is added to the wound at the time of surgery, and 
the soldier is evacuated to a rear military hospital. Accompanying the soldier is something 
new in wound treatment – a petri plate. In addition to the standard “incision and 
drainage”, this soldier has had his injury cultured and the petri plate will accompany him. 
When he arrives at the hospital the petri plate will be inspected and if there are no 
streptococci and fewer than five colonies of all other bacteria, the wound will be closed.  
If these criteria are not met, the wound will be left open to heal by secondary intention.  
Guidance by quantitative microbiology became quite common in the French army in 
World War I, the first time the counting of bacteria was used to dictate therapy. Soon 
after the war, however, the procedure was forgotten. 
 
Edberg (1) also points out that it was not until 1955, nearly 40 years later, that there was a 
revival, in place to the present day, in the use of quantitative microbiology to guide 
treatment of traumatic injuries. 
 
In addition to monitoring of medical infections for their microbiological composition, the 
discovery of antibiotics in 1928 by Sir Alexander Fleming marked the start of antimicrobial 
susceptibility testing in the field of clinical microbiology. As depicted on the cover of this 
thesis, Fleming (2) noted a zone of staphylococcal growth inhibition immediately adjacent 
to penicillin-producing mold colonies on a contaminated agar plate that had been left 
inadvertently exposed to the outside environment in his laboratory. This observation of the 
inhibitory effects of penicillin on staphylococcal growth represents the outcome of the first 
known in vitro antibiotic susceptibility test. Over the ensuing decades, in vitro antibiotic 
susceptibility testing has greatly evolved to its present-day widespread use in infectious 
disease management (3). 
  
As recognized by Murray (4), even though antimicrobial susceptibility testing is generally 
limited to assessing interactions between cultivable microorganisms and test antimicrobials 
within an in vitro setting, and fails to capture the many in vivo host/bacterial pathogen 
interactions that influence the clinical status of an infectious process (5), clinical data for 
many bacterial infections demonstrate a good correlation between in vitro antimicrobial 
susceptibility test results and in vivo clinical patient responses. In general, it is recognized 
that patients with antibiotic drug-resistant bacterial pathogens in a clinical infection more 
frequently demonstrate a poorer microbiological response to antibiotic therapy than patients 
with bacterial pathogens shown to be sensitive in vitro to the antibiotic (4). As a result, the 
identification of antibiotic-resistant pathogens plays a key role in clinical decision-making 
relative to treatment of many medical infections. There is presently in infectious disease 
management an increased reliance upon in vitro antimicrobial susceptibility test results to 
help guide selection and administration of the most appropriate antimicrobial therapies in 
order to enhance patient outcomes and minimize clinical treatment failures, since use of 
antimicrobials which fail to exert activity against bacterial pathogens in an infection is 





It is within this historical background and context that this thesis examines the occurrence 
of antibiotic resistance among bacterial pathogens associated with human periodontitis and 
peri-implantitis infections. 
 
Human periodontitis: an overview   
 
Periodontitis is a destructive form of periodontal disease that adversely impacts tooth-
supporting soft and hard tissues, and ultimately, may lead to loss of natural teeth in the 
human dentition. Periodontitis is considered to be multifactorial in its etiology, but 
nevertheless, is primarily driven in its progression by tooth surface growth of highly-
organized, polymicrobial, biofilms of pathogenic bacteria that comprise what is commonly 
referred to as dental plaque.  
 
In periodontal health, teeth are anchored to maxillary and mandibular alveolar bone by 
numerous Sharpey’s fibers, composed of Type I collagen, that are the main constituent of 
the periodontal ligament covering tooth root surfaces from the cementoenamel junction to 
the apices of teeth. Sharpey’s fibers are embedded, at one end, into cementum on tooth root 
surfaces, and on the other end, into alveolar bone proper that surrounds and houses tooth 
roots. The attachment apparatus of teeth is thus composed of periodontal ligament, tooth 
cementum, and alveolar bone (6) (Figure 1).     
 
                                     
         
Figure 1. Cross-sectional depiction of tooth interface with gingival tissues and alveolar bone  
                in periodontal health. Modified from Slots & Rams (6). 
 
Gingival soft tissues surrounding teeth, and covering the periodontal attachment apparatus, 
are relatively devoid of inflammatory cells in periodontal health, and maintain an 
interfacing knife-edge marginal relationship with tooth surfaces. The gingival sulcus in 
periodontal health (Figure 1) is shallow (1-3 millimeters) in its coronal-apical dimension, 
and does not bleed upon probing with gentle insertion and apical advancement of a 
periodontal probe instrument (Figure 2). 
 
A = periodontal ligament 
B = alveolar bone 
C = tooth cementum 
D = outer epithelium of gingiva 
E = sulcular epithelium of gingiva 
F = junctional epithelium 
G = gingival sulcus 
H = cementoenamel junction 
I = tooth enamel 






    
 
Figure 2.  (left) Healthy gingival tissues around a natural tooth exhibiting no visible inflammation  
                 and a shallow gingival sulcus measured (right) with a periodontal probe. 
 
In contrast, periodontitis induces a progressive loss from teeth of anchoring gingival 
connective tissue and periodontal ligament fibers, along with resorption of surrounding 
crestal alveolar bone. The junctional epithelium, which in periodontal health is normally 
located with its most coronal aspect at the cementoenamel junction, migrates apically as 
progressive destruction of periodontal ligament fibers occurs subjacent to it (Figure 3).     
 
    
  
Figure 3. Cross-sectional depiction of tooth interface with gingival tissues and alveolar bone  
                in periodontitis. Modified from Slots & Rams (6). 
                                   
Clinically, periodontitis is characterized by the presence of gingival inflammation, with 
gingival tissues appearing red in color and edematous, and bleeding on probing is detected 
with a periodontal probe. Marked increases in periodontal probing depths are measured 
adjacent to periodontitis-affected tooth surfaces as the gingival sulcus is transformed into a 
periodontal pocket, with moderate (4-PLOOLPHWHUVDQGVHYHUH PLOOLPHWHUVSURELQJ
depths forming that may progress, in the absence of periodontal therapy, to the tooth root 
apex (Figure 4).      
 
A = periodontal ligament loss 
B = alveolar bone loss 
C = apical migration of junctional  
        epithelium  
D = ulcerations in pocket  
        epithelium  
E = inflammatory cell infiltration  
        of gingival tissues 
F = pathogenic dental plaque  
        subgingival biofilm 







Figure 4.  Inflamed gingival tissues on tooth affected by periodontitis, with bleeding on probing  
                 and an 8 millimeter probing depth. 
 
With advanced periodontal tissue breakdown, increased tooth mobility may be detected 
upon gentle clinical luxation of teeth in a facial-lingual direction, and radiographic loss of 
crestal alveolar bone height and density may be noted. 
 
Periodontitis is a relatively common affliction in humans around the world.  In the United 
States, the most recent national epidemiologic prevalence survey of periodontitis involved 
the clinical examination of 3,742 dentate adults, aged 30 years and older, in the civilian 
non-institutionalized population. Clinical periodontal attachment loss (as measured from 
the cementoenamel junction of teeth to the most apical periodontal probe penetration into 
periodontal pockets and gingival sulci) and periodontal probing depths (as measured from 
the free gingival margin to the most apical periodontal probe penetration into periodontal 
pockets and gingival sulci) were assessed in each of the examined adults at six sites per 
tooth on all teeth except third molars (7). It is estimated from this data that approximately 
RIWKHSRSXODWLRQVDPSOHUHSUHVHQWLQJPLOOLRQ8QLWHG6WDWHVGHQWDWHDGXOWV
years old, exhibited some form of periodontitis, with severe and moderate periodontitis 
found in 8.5% and 30% of the study population, respectively (7). In addition, a particularly 
high prevalence of periodontitis was noted in elderly persons, with 64% of dentate adults 
DJHG   \HDUV SUHVHQWLQJ ZLWK HLWKHU PRGHUDWH RU VHvere periodontitis (7). Moreover, 
periodontitis was found to be significantly higher or highest among certain population 
groups in the United States, including males, Mexican Americans (Hispanic) (followed 
closely by blacks, who were both significantly more affected by periodontitis than whites), 
less educated (with less than high school graduation), poor (below federal poverty levels in 
income), and current smokers (7). In addition to these potential risk factors, other research 
studies have associated a family history of periodontitis, specific genetic polymorphisms, 
certain systemic diseases (such as uncontrolled diabetes mellitus), obesity, poor oral 
hygiene, subgingival calculus, overhanging margins of dental restorations, and psycho-
social stress, with an increased risk of periodontitis (8). Additional predisposing conditions 
to periodontitis have been proposed, and are under study (9). 
 
Subgingival infection with specific pathogenic bacteria, methanogenic archaea, and possi-
bly activation of certain herpesviruses in gingival tissues, have been related to the onset and 
progression of human periodontitis (6,8,10-12). Among the major bacterial species 





Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Treponema denticola 
and other oral spirochetes, Tannerella forsythia, Selenomonas noxia, Prevotella intermedia/ 
nigrescens, Dialister pneumosintes, Fusobacterium nucleatum, Fusobacterium animalis, 
and Campylobacter rectus. Several gram-positive species have been identified with perio-
dontitis, including Parvimonas micra, Filifactor alocis, Eubacterium nodatum and other 
Eubacterium species, and each of the three anginosus streptococci group species, Strepto-
coccus constellatus, Streptococcus intermedius, and Streptococcus anginosus.   
 
In some periodontitis patients, atypical subgingival periodontal pathogens may be present 
in high numbers, such as the gram-positive facultative species Enterococcus faecalis, 
Staphylococcus aureus, Staphylococcus epidermidis, and other staphylococci; the gram-
negative facultative organisms classified as enteric rods and pseudomonads; and yeasts 
most frequently identified as Candida albicans. Microbial species presently classified as 
phylotypes, since they have yet to be successfully cultivated in laboratory settings, but can 
be identified via 16s ribosomal RNA bacterial gene analysis, have also been recovered from 
subgingival biofilms in periodontitis (13).   
 
In addition to specific bacterial species, Methanobrevibacter oralis, a methanogenic 
Archaea species that has the capability to support anaerobic bacterial growth via 
interspecies hydrogen transfer, is increased in the subgingival pocket environment with 
periodontitis severity, decreased with successful periodontal therapy, and absent in perio-
dontal health (11). Herpesviruses, such as cytomegalovirus and Epstein Barr virus, when 
present in an active lytic phase in gingival tissues, may be locally-immunosuppressive and 
promote overgrowth of periodontopathic bacteria in periodontal pockets (12).  
 
As a result, the onset of periodontitis involves a series of complex interactions between a 
variety of local and systemic host susceptibility factors with the effects of pathogenic 
bacterial biofilm growth on tooth surfaces, and invasion into gingival tissues adjacent to 
tooth surfaces, leading to detrimental immunoinflammatory reactions which induce perio-
dontal connective tissue loss and alveolar bone resorption around affected teeth (Figure 5). 
 
                                 
 
Figure 5.  Model relating the interactions between host risk factors and pathogenic bacterial  
                 populations that result in inflammatory-mediated periodontal tissue breakdown  





Beyond the loss of teeth ultimately resulting in edentulism (a loss of all natural teeth), 
periodontitis, and periodontitis-associated microorganisms, have been implicated in the 
pathogenesis of a number of systemic medical conditions at non-oral body sites, including, 
but not limited to, cardiovascular disease, stroke, rheumatoid arthritis, premature/low birth 
weight pregnancy outcomes, tubal-ovarian abscess, infectious arthritis of knee, aspiration 
pneumonia and other types of lung infections, chronic conjunctivitis, and clenched-fist 
wounds (14,15). Periodontitis can thus not only adversely affect teeth in the oral cavity, and 
their normal functions in supporting mastication of food, stimulating maintenance of 
alveolar bone in the jaws, and contributing to dental esthetics, but it may also contribute to 
a decreased life-span for afflicted individuals by potentiating serious systemic medical 
disorders (14,15). 
 
Interestingly, the exact etiologic mechanism underlying the onset or “triggering” of perio-
dontitis disease-activity remains uncertain, and a recent systematic review even questions 
the role of pathogenic bacteria in the pathogenesis of periodontitis (16). While pathogenic 
bacterial biofilms on tooth surfaces appear necessary to initiate periodontal disease, it is 
noteworthy that most periodontal tissue damage from periodontitis is largely attributable to 
hyper-responsive host immunoinflammatory reactions to pathogenic bacterial biofilms (17).      
 
Treatment of periodontitis  
 
Because host-related risk factors for periodontitis are immutable or difficult to 
therapeutically alter, most periodontitis treatment strategies focus on suppression or 
elimination of pathogenic bacterial biofilms on supragingival and subgingival tooth 
surfaces. Mechanical debridement of pathogenic dental plaque biofilms (carried out with or 
without periodontal surgical flap access), and meticulous patient supragingival home 
plaque control, form the traditional basis for treatment of periodontitis. However, despite 
years of documented success with this type of treatment approach, a subset of periodontitis 
patients suffer further progressive periodontal breakdown (18). While a number of factors 
may be responsible for such treatment failures, such as inadequate root instrumentation, 
poor home oral hygiene compliance by patients with supragingival plaque control, presence 
of plaque-retentive dental restorations, it is also clear that many treatment failures in 
periodontitis are related to, despite extensive efforts of clinicians and patients, a persistence 
of a pathogenic subgingival dental plaque microbiota (19,20). In one such study by Rams et 
al. (19), 25 of 78 (32.1%) adults with severe periodontitis treated with root debridement, 
surgical pocket elimination, three-month maintenance care, and good supragingival plaque 
control experienced recurrent periodontitis disease activity within 12-months post-
treatment. In multivariate analysis, the post-treatment persistence of elevated subgingival 
proportions of one or more of five major periodontal bacterial pathogens (i.e., P. gingivalis, 
A. actinomycetemcomitans, P. intermedia/nigrescens, P. micra, C. rectus) was associated 
with a statistically significant 2.5 (150%) excess relative risk for periodontitis recurrence 
within 12-months post-treatment (19). Similarly, Mombelli et al. (21) reported 59% of 17 
adults with chronic periodontitis remaining culture-positive for subgingival P. gingivalis 
after extensive non-surgical root debridement and supragingival dental plaque control, with 
a direct correlation found between residual deep periodontal probing depths, indicative of a 
poor clinical treatment outcome, and persistence of subgingival P. gingivalis. Using digital 
computer subtraction radiology to detect small changes in crestal alveolar bone mass, 





mechanical root debridement of chronic periodontitis patients to be strongly associated with 
elevated risk of subsequent progressive periodontal bone loss (31.9 odds ratio; 84% 
positive predictive value).   
 
To augment the antimicrobial effects of conventional mechanical-surgical periodontal 
therapy, and to better suppress or eliminate recalcitrant subgingival periodontal bacterial 
pathogens, systemic antibiotic therapy has been increasingly employed in the treatment of 
periodontitis. The use of systemic antibiotics in periodontal disease therapy represents a 
conceptual shift in the field of periodontology towards application of an anti-infective 
treatment strategy, where specific disease-associated bacterial pathogens, such as P. 
gingivalis, are primarily targeted for suppression or elimination from oral cavity of 
periodontitis patients (Figure 6).    
 
       
Figure 6.  Specific periodontal bacterial pathogens are primary therapeutic targets in an  
                 anti-infective periodontal disease treatment model, with anatomical abnormalities  
                 in the periodontium being secondarily targeted for alteration. However, successful  
                 treatment interventions on both microbiological and anatomical targets help attain  
                 periodontal clinical goals and optimize patient outcomes. 
 
Clinical trials, systematic reviews, and meta-analysis reported during the past decade have 
documented a beneficial clinical and microbiological effect of systemic periodontal 
antibiotic therapy on periodontitis patients (23-29). Antibiotics shown to have some 
efficacy in periodontitis therapy include single drug regimens with tetracycline-HCl, 
minocycline, doxycycline, amoxicillin, clindamycin, metronidazole, azithromycin, and 
moxifloxacin, as well as combination drug regimens involving amoxicillin plus metro-
nidazole, and ciprofloxacin plus metronidazole (23-29). 
 
Considerable questions remain to be resolved as to how to identify which periodontitis 
patient will benefit from systemic antibiotic therapy, and how to select the most appropriate 
antibiotic for the specific patient. An indication of a differential response to systemic 
antibiotic therapy among patients is illustrated by data showing that the administration of 
systemic amoxicillin plus metronidazole therapy on periodontitis patients leads to some 
patients with an enhanced clinical outcome relative to conventional non-antibiotic, 
mechanical-surgical treatment approaches, whereas other patient outcomes are found to be 





Several explanations may account for an inadequate patient response to systemic periodon-
tal antibiotic therapy.  Because systemic antibiotics are generally prescribed to periodontitis 
patients for unsupervised oral consumption in home settings, inadequate compliance with 
taking the antibiotic regimen as instructed may occur. Loesche et al. (33) reported only 
56% of 18 periodontitis patients were compliant with a prescribed systemic metronidazole 
drug regimen, with a significantly greater reduction of periodontal surgical needs found in 
compliant patients, as compared to non-compliant individuals. 
 
Variability among patients in their ability to successfully absorb oral antibiotics may also 
impair systemic periodontal antibiotic therapies. Sakellari et al. (34) found serum and 
gingival crevicular fluid drug concentrations to vary widely among periodontitis subjects 
consuming tetracycline family antibiotics, and concluded that “poor absorption of orally-
administered tetracyclines in many individuals may account for much of the variability in 
clinical response to antibiotics observed in practice.” 
 
Antibiotic drug penetration into intact dental plaque biofilms is another problematic 
challenge in periodontics. Markedly higher minimal inhibitory concentration values, up to 
250 times greater, of antibiotics are needed when periodontal bacterial pathogens are 
organized in dental plaque biofilms, as compared to being separated apart as planktonic 
cells (35). 
 
In addition, targeted dental plaque microorganisms need to be susceptible to therapeutic 
concentrations of antibiotics in order to be inhibited by them. Limited data indicates that 
antibiotic-resistant periodontal bacterial pathogens have been increasing in their occurrence 
over time in the United States. Walker (36) observed an increased in vitro resistance to 
amoxicillin, tetracycline, and macrolide antibiotics among subgingival bacteria tested in the 
early 1990s as compared to the early 1980s. More recently, an increased occurrence of 
clindamycin resistance in subgingival P. gingivalis clinical isolates was reported in 2003 
(37). An urgent need exists to better quantify the extent to which antibiotic resistance 
occurs among pathogenic subgingival bacterial species in human periodontitis patients. 
 
Human peri-implantitis: an overview 
 
Dental implants, which are employed as replacements for lost natural teeth in the oral 
cavity, may be affected by marginal bone loss that may lead to loss of the implants. Dental 
implants, in comparison to teeth, do not possess an attachment apparatus comprised of 
cementum, periodontal ligament and alveolar bone. Instead, successful titanium osseo-
integrated dental implants ankylose after a healing phase to adjacent alveolar bone after 
their surgical placement into osteotomy channels created where natural teeth were lost.   
 
Controversy exists relative to the cause of marginal bone loss on dental implants, with three 
major theories currently being debated (38). First, is the “infection” theory, which regards 
peri-implantitis to be a destructive infectious complication of dental implants, analogous to 
periodontitis on natural teeth. The primary etiologic factor in peri-implantitis is considered 
to be pathogenic bacterial biofilm growth on dental implant surfaces, with possible 
contributions by methanogenic Archaea and herpesviruses (39-41). If allowed to persist 
without therapeutic intervention, immunoinflammatory host tissue reactions may occur that 





implant probing depths, and progressive peri-implant crestal alveolar bone loss. The 
marginal alveolar bone loss may ultimately encompass the apical extent of the dental 
implant, leading to dental implant mobility and loss (exfoliation). Peri-implantitis is 
estimated to occur in 10.7% to 47.2% of dental implant patients after 10 years of post-
treatment observation (Figure 7) (42).  
 
Figure 7. Radiograph appearance of peri-implantitis on a dental implant.   
               (left) Dental implant status in 1994 with normal crestal alveolar bone height (arrow), as  
               well as open margin between the dental implant crown and fixture.  
               (right) Dental implant in 1998 - note marked loss of crestal alveolar bone height (arrow). 
               Clinical bleeding on probing and deep peri-implant probing depths were detected, along  
               with high submucosal proportions of P. gingivalis, P. intermedia/nigrescens, and P. micra. 
 
The “adverse occlusal load” theory suggests that excessive overloading of dental implants 
by heavy occlusal forces may initiate progressive marginal bone loss leading to implant 
failure (38). Isidor (43), using a monkey model, found dental implants restored in supra-
occlusal contact with an “antagonizing splint” (occlusal overload) exhibited significantly 
greater marginal bone loss over 18 months, and greater dental implant loss, as compared to 
dental implants subjected to a dental plaque-accumulating cotton cord placed around the 
peri-implant marginal soft tissues. Interestingly, when occlusal overloading is combined 
with ligature-induced, bacterial-mediated, peri-implant inflammation, peri-implant angular 
bone loss is significantly increased on buccal and lingual surfaces in beagle dogs than is 
observed with either risk factor alone (44). 
 
The “compromised healing/adaptation” theory proposes that local and systemic host factors 
that compromise post-treatment healing after dental implant placement, such as poor bone 
quality, genetic factors, traumatic implant surgery, and improper prosthodontic treatment 
planning, are responsible for most, if not all, dental implant failures, with little contribution 
by submucosal bacterial populations (38).    
 
It is not presently known which of these three theories, or combinations of them, are 
applicable to the majority of dental implant failures. It is of interest that when systemic 
antibiotics are given as adjuncts to mechanical debridement and/or surgical procedures on 
peri-implantitis-affected dental implants heavily colonized by putative bacterial pathogens, 
marked clinical and/or radiographic improvements occur, leading to arrest of the peri-
implantitis lesions (45-47). This suggests the applicability of the “infection” theory, and a 





role for systemic antibiotics, for at least a subset of human dental implants experiencing 
marginal bone loss.   
 
Purpose and goals of thesis  
 
The hypothesis underlying this thesis is that antibiotic-resistant periodontal pathogens are 
present in the subgingival microbiota of United States periodontitis and peri-implantitis 
patients that have the ability to survive therapeutic concentrations of systemic antibiotics 
that are commonly prescribed in the treatment of these two oral diseases. At present, little 
or no data of recent origin is available on the occurrence of antibiotic-resistant bacterial 
pathogens in periodontitis and peri-implantitis patients in the United States. 
 
The study of antibiotic-resistant periodontal and peri-implant bacterial pathogens may help 
account for clinical treatment failures in periodontitis and peri-implantitis therapies. If 
substantial antibiotic resistance is detected in affected patients, then new clinical strategies, 
which encompass assessments of subgingival and submucosal bacterial pathogen antibiotic 
susceptibility testing as part of treatment planning for periodontitis and peri-implantitis 
patients, may be more appropriate for clinical periodontal and oral implantology practice.  
 
To help address the issue of how frequent are antibiotic-resistant periodontal pathogens 
found in United States periodontitis patients, an in vitro study was conducted on the 
antibiotic susceptibility of subgingival clinical isolates of S. constellatus and S. intermedius 
(Chapter 2), since little data is available in the scientific literature on the occurrence of 
antibiotic resistance among these species. A similar in vitro evaluation of antibiotic sus-
ceptibility testing was carried out on subgingival clinical isolates of E. faecalis, which may 
occur on occasion in refractory periodontitis patients, and for which little antibiotic 
resistance data is also available for strains recovered from periodontal lesions in the United 
States (Chapter 3).   
 
Chapter 4 evaluated a wide range of organisms in the cultivable subgingival microbiota of 
FKURQLF SHULRGRQWLWLV VXEMHFWV LQ WKH8QLWHG 6WDWHV WR IXUWKHU DVVHVV WKH RFFXUUHQFH RI ȕ-
lactamase enzyme producing subgingival bacterial test species, which would potentially 
KDYHWKHDELOLW\WRGHJUDGHȕ-lactam antibiotics, leaving them pharmacologically inactive as 
antimicrobial agents, and compromising their efficacy in systemic periodontal antibiotic 
therapy. 
 
Chronic periodontitis subjects in the United States were also evaluated in Chapter 5 for the 
occurrence of subgingival periodontal pathogens that exhibited in vitro resistance to thera-
peutic breakpoint concentrations to several antibiotics used frequently in clinical perio-
dontal practices, including clindamycin, doxycycline, amoxicillin, metronidazole, and the 
joint use of amoxicillin and metronidazole. A similar evaluation of United States chronic 
periodontitis subjects was carried in Chapter 6 with a focus on the macrolide antibiotic 
spiramycin alone, and with metronidazole. 
 
Chapter 7 aimed to assess the occurrence of in vitro antibiotic resistance among sub-






These studies were undertaken with the goal of providing better characterization of the 
occurrence of antibiotic-resistant pathogens in chronic periodontitis and peri-implantitis 
patients in the United States. An additional goal was to identify, among a selected panel of 
putative periodontal and peri-implant bacterial pathogens, those subgingival and sub-
mucosal species which most frequently exhibit in vitro resistance to antibiotics pertinent to 
treatment of periodontitis and peri-implantitis. 
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Purpose: Streptococcus constellatus and Streptococcus intermedius in subgingival dental 
plaque biofilms may contribute to forms of periodontitis that resist treatment with 
conventional mechanical root debridement-surgical procedures, and may additionally 
participate in some extraoral infections. Since systemic antibiotics are often employed in 
these clinical situations, and little is known of the antibiotic susceptibility of subgingival 
isolates of these two bacterial species, this study determined the in vitro susceptibility to six 
antibiotics of fresh S. constellatus and S. intermedius clinical isolates from human 
periodontitis lesions.   
 
Materials and methods: A total of 33 S. constellatus and 17 S. intermedius subgingival 
strains, each recovered from separate chronic periodontitis patients, were subjected to 
antibiotic gradient strip susceptibility testing with amoxicillin, azithromycin, clindamycin, 
ciprofloxacin and doxycycline on blood-supplemented Mueller-Hinton agar, and to the 
inhibitory effects of metronidazole at 16 mg/L in an enriched Brucella blood agar dilution 
assay. CLSI and EUCAST interpretative standards were used to assess the results.   
 
Results: Clindamycin was the most active antibiotic against S. constellatus (MIC90 = 0.25 
mg/L), with amoxicillin most active against S. intermedius (MIC90 = 0.125 mg/L). 30% of 
the S. constellatus and S. intermedius clinical isolates were resistant in vitro to doxycycline, 
98% were only intermediate in susceptibility to ciprofloxacin, and 90% were resistant to 
metronidazole at 16 mg/L.   
 
Conclusions: Since subgingival S. constellatus and S. intermedius exhibit variable 
antibiotic susceptibility profiles, potentially complicating selection of periodontitis 
antibiotic therapy, microbiological analysis that encompasses antimicrobial sensitivity 
testing may be particularly helpful in periodontal treatment planning of species-positive 













Streptococcus constellatus and Streptococcus intermedius are two phenotypically and 
genetically distinct members of the classic “Streptococcus milleri group” of bacteria now 
taxonomically classified as anginosus group streptococci (1). The two species are 
considered commensal organisms in the human upper respiratory, gastrointestinal, and 
female urogenital tracts, but may act as life-threatening opportunistic pathogens in deep-
seated abscesses and purulent surgical infections when translocated into normally sterile 
body sites (1).   
  
In the human oral cavity, S. constellatus and S. intermedius preferentially inhabit 
subgingival dental plaque biofilms on interproximal tooth surfaces in untreated perio-
dontitis patients (2), where after periodontal root instrumentation, no decrease in their 
detection rate is reported to occur (3). The two species also show a predilection to colonize 
oral soft tissue surfaces, such as the hard palate, floor of the mouth, and dorsum of the 
tongue, to a degree similar or greater than in subgingival tooth sites (4), which provides a 
potential post-periodontal treatment reservoir source for re-seeding of periodontal pockets 
by the organisms. Increases in adrenaline and noradrenaline hormonal levels in response to 
psychosocial-emotional stress, a recognized risk factor in the development and progression 
of human periodontitis (5), significantly stimulates in vitro growth of S. constellatus and S. 
intermedius (6), which may further favor their oral selection and outgrowth in periodontitis-
susceptible subjects. As a result, the oral colonization properties of S. constellatus and S. 
intermedius, along with their strong anti-phagocytic resistance to human polymorpho-
nuclear leukocytes (7), likely contributes to their association with forms of destructive 
periodontal disease that do not respond to conventional mechanical root scaling-surgical 
treatment procedures (8-10). In addition, these species are associated with brain abscesses 
and other extraoral infections when they are disseminated outside of the oral cavity via 
bacteremia through inflamed gingival tissues (11,12).  
 
Since antimicrobial chemotherapy is frequently employed to treat patients with refractory 
periodontitis and various extraoral infections (13), the antibiotic susceptibility of sub-
gingival S. constellatus and S. intermedius can be a decisive factor in the selection and 
clinical success of prescribed anti-infective drug regimens. Because relatively little is 
presently known about the antibiotic sensitivity of periodontal strains of S. constellatus and 
S. intermedius, the purpose of this study was to determine the in vitro susceptibility to six 
antibiotics of fresh clinical isolates of these two species recovered from human perio-
dontitis lesions. 
 




A total of 33 S. constellatus and 17 S. intermedius fresh clinical isolates were recovered on 
enriched Brucella blood agar primary isolation plates, as previously described (14), by the 
Oral Microbiology Testing Service Laboratory at Temple University School of Dentistry, 
Philadelphia. The species were isolated from subgingival plaque biofilm specimens 
removed from 50 systemically-healthy adults with untreated advanced chronic periodontitis 




geographically living in eastern United States), as diagnosed by 50 periodontists in private 
dental practices, with each subject contributing one isolate of either test species. S. 
constellatus comprised a mean of 8.9 ± 0.2 (SE) % (range 0.1-46.8%), and S. intermedius 
averaged 4.1 ± 1.6 (SE) % (range 0.1-17.4%), in the cultivable subgingival microbiota of 
the species-positive patients.   
 
S. constellatus was defined as gram-positive, lactose MUG-test negative (16), non-motile, 
facultatiYH FRFFL GHPRQVWUDWLQJ VPDOO P LQGLDPHWHUZKLWH RSDTXH FLUFXODU ȕ-
hemolytic, surface colonies with irregular edges. The species were further positive for 
acetoin production (Voges-3URVNDXHUWHVWSRVLWLYHQHJDWLYHIRUȕ-D-fucosidase, and posi-
WLYH IRU Į-D-JOXFRVLGDVH HQ]\PH DFWLYLW\ ZLWK RU ZLWKRXW FRQFXUUHQW ȕ-D-glucosidase 
activity), as determined using a commercial test kit (Fluo-Card Milleri test kit, Key 
Scientific Products Co., Stamford, TX, USA) (17). S. intermedius was recognized as gram-
positive, lactose MUG-test positive, non-motile, facultative cocci exhibiting small (< 0.5 
μm in diameter), dry, white, raised colonies with wrinkled edges, which were positive for 
DFHWRLQ ȕ-D-IXFRVLGDVH ȕ-D-JOXFRVLGDVH DQG Į-D-glucosidase (17). These phenotypic 
identification criteria for S. constellatus and S. intermedius are reported to provide 96-100% 
agreement with 16S rRNA gene sequencing analysis of the species (17-19). 
 
In vitro antimicrobial susceptibility testing  
 
Pure culture cell suspensions of each of the S. constellatus and S. intermedius clinical 
isolates were adjusted to a 0.5 McFarland turbidity standard, and streaked with sterile 
cotton-tipped swabs onto 150 mm diameter plates containing Mueller-Hinton agar with 5% 
sheep blood. After drying, predefined antibiotic gradient strips (E-test, bioMérieux, 
Durham, NC, USA) (20), containing amoxicillin, azithromycin, clindamycin, ciprofloxacin 
or doxycycline, were applied onto the inoculated media surfaces. After 24 hours of 
incubation at 35°C in ambient air-5% CO2, the intersection between the border of test 
species growth and the antibiotic gradient strip drug scale for each antimicrobial was read 
to determine the in vitro minimum inhibitory concentration (MIC) value, following 
manufacturer’s instructions. Streptococcus pneumoniae ATCC 49619 was employed as a 
quality control strain in the antibiotic gradient strip susceptibility testing.   
 
For in vitro assessment of metronidazole susceptibility, a separate agar dilution assay with 
antibiotic-supplemented enriched Brucella blood agar was used, as previously described 
(14, 21) to evaluate the inhibitory effects of metronidazole at a concentration of 16 mg/L on 
each of the S. constellatus and S. intermedius test species. Bacteroides thetaiotaomicron 
ATCC 29741, Clostridium perfringens ATCC 13124, and a multi-antibiotic-resistant 
clinical periodontal isolate of Fusobacterium nucleatum were employed as positive and 




MIC50 and MIC90 values for each antibiotic were defined as the MIC level that completely 
inhibited 50% and 90%, respectively, of the tested subgingival clinical isolates. MIC 
interpretative standards developed by the Clinical and Laboratory Standards Institute 
(CLSI) for Streptococcus viridans group species, which includes S. constellatus and S. 
intermedius, were used to categorize the in vitro inhibitory activity of azithromycin and 




clindamycin against the test isolates (22). Clinical breakpoint values developed by the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) for viridans 
group streptococci were used for amoxicillin susceptibility testing, and EUCAST break-
points for S. pneumonia were applied to doxycycline and ciprofloxacin test results (23), 
since no CLSI interpretative guidelines for these antibiotics against S. constellatus and S. 
intermedius are available. Clinical isolates with MIC values less than or equal to the 
antibiotic susceptibility breakpoint concentration were classified as “susceptible”, with 
those more than or equal to antibiotic resistance breakpoint concentrations identified as 
“resistant”. Test strains with MIC values in-between antibiotic susceptibility and resistance 
breakpoints were designated as “intermediate”.   
 
Approval for this study was provided by the Temple University Human Subjects 






The antibiotic gradient strip MIC values for the S. pneumoniae ATCC 49619 quality 
control strain for amoxicillin, azithromycin, clindamycin, ciprofloxacin and doxycycline, as 
well as the test results for the three quality control strains subjected to in vitro 
metronidazole resistance testing, were within the expected ranges and outcomes (data not 
shown).  
 
In vitro antibiotic susceptibility testing  
 
Table 1 presents the cumulative distribution of MIC antibiotic values against all tested 
periodontal S. constellatus and S. intermedius clinical isolates.  Table 2 provides the MIC 
range, MIC50, and MIC90 for these antibiotics against periodontal S. constellatus and S. 
intermedius clinical isolates individually, as well as together, since only relatively small 
differences in antibiotic sensitivity were found between the two species. By possessing the 
lowest MIC90 values, clindamycin was the most active antibiotic against S. constellatus 
(MIC90 = 0.25 mg/L), whereas amoxicillin was the most active against S. intermedius 
(MIC90 = 0.125 mg/L). Both drugs were 32 times more active against the test species than 
doxycycline, which exhibited MIC90 values of 8 mg/L against S. constellatus, and 4 mg/L 
against S. intermedius. Amoxicillin, azithromycin, and ciprofloxacin demonstrated a simi-
lar magnitude of antimicrobial inhibition against periodontal S. constellatus (MIC90 = 0.38 
mg/L for each drug). In comparison, amoxicillin and azithromycin were more active against 
S. intermedius than ciprofloxacin.      
 
Table 2 also presents the number and percentage of test strains resistant to antibiotic break-
point concentrations. Periodontal S. constellatus and S. intermedius were overall most 
frequently resistant in vitro to doxycycline, with 30% of all test strains yielding MIC values 
above the doxycycline resistance breakpoint concentration. No periodontal S. constellatus 
and S. intermedius were resistant in vitro to amoxicillin, and only a low frequency of in 
vitro resistance was detected to azithromycin, clindamycin, and ciprofloxacin (2-6% of 
clinical isolates). However, 98% of all S. constellatus and S. intermedius periodontal 



































































































































































































































































   
   
   
   







































































































































































































































































































































































































































































































































































































































































































































































































































































































The present study provides in vitro antibiotic susceptibility test results on the largest 
number to date (n = 50 total) of S. constellatus and S. intermedius clinical isolates of sub-
gingival origin recovered from patients in the United States with chronic periodontitis.       
In general, the antibiotic susceptibility profiles of subgingival S. constellatus and S. 
intermedius parallel those of strains of the species recovered at other body sites (24). 
 
Several of the study findings may have clinically relevant therapeutic implications with 
regard to human periodontitis management. First, 30% of the subgingival S. constellatus 
and S. intermedius clinical isolates were resistant in vitro to doxycycline. Interestingly, this 
corresponds with a nearly identical level of doxycycline non-susceptibility recently 
reported in S. constellatus and other anginosus group streptococci isolated from human, 
non-periodontal, submucosal oromaxillofacial inflammatory infiltrates and odontogenic 
abscesses in Germany (25). Resistance to doxycycline, as well as other tetracycline family 
antibiotics, among subgingival S. constellatus and S. intermedius may compromise clinical 
periodontal treatment outcomes, and increase risk of progressive periodontitis, as a result of 
drug-resistant strains surviving in periodontal pockets and oral tissues during active 
doxycycline or tetracycline therapy. In this regard, high numbers of tetracycline-resistant S. 
intermedius and Streptococccus anginosus were found persisting, in the absence of other 
putative periodontal pathogens, in post-treatment subgingival dental plaque biofilms in a 
patient with refractory periodontitis experiencing a poor clinical response to systemic 
tetracycline-HCl therapy administered in conjunction with mechanical root instrumentation 
and periodontal flap surgery (26). Similarly, doxycycline-resistant subgingival S. 
constellatus and S. intermedius were detected at baseline and persisted post-treatment in 
over 50% of monitored periodontal sites in patients with chronic periodontitis where 
systemic doxycycline therapy failed to provide significant clinically beneficial effects (27).  
In another clinical study of refractory chronic periodontitis (9), baseline subgingival 
recovery of S. constellatus DWRIWRWDO'1$SUREHFRXQWVFRQIHUUHGDQRGGVUDWLR
for marked progressive periodontal attachment loss within 12 months after the completion 
of a 28-day systemic tetracycline drug regimen and periodontal flap surgery. These data, 
along with the present in vitro susceptibility findings, suggest a need for clinical caution in 
the use of doxycycline and other tetracycline family antibiotics in periodontal therapy 
employed on patients with high numbers of subgingival S. constellatus and/or S. 
intermedius.   
 
As expected, nearly all subgingival S. constellatus and S. intermedius clinical isolates were 
resistant to metronidazole at a 16 mg/L concentration, consistent with clinical studies 
demonstrating no statistically significant alterations in drug-resistant subgingival strains of 
the two species following systemic metronidazole administration in patients with perio-
dontitis (28). This highlights a potential limitation of single antibiotic drug regimens 
involving metronidazole alone in periodontitis patients harboring S. constellatus and S. 
intermedius within polymicrobial subgingival dental plaque biofilms.  
 
Since ciprofloxacin demonstrated only marginal in vitro activity against periodontal S. 
constellatus and S. intermedius, with nearly all clinical isolates only intermediate in their 
drug susceptibility to this first-generation fluoroquinolone, its potential clinical value is 




likely contrast to moxifloxacin, which appears to exert greater antimicrobial activity against 
oral anginosus group streptococci (25). The clustering of ciprofloxacin MIC values for the 
test species near the drug’s non-susceptible breakpoint concentration was also found by 
Asmah et al. (29) among anginosus group streptococci isolated from pyogenic abscesses at 
non-periodontal body sites.   
 
No test isolates were resistant in vitro to amoxicillin. Consistent with this, clinical studies 
have shown systemic therap\ ZLWK DPR[LFLOOLQ SOXV WKH ȕ-lactamase inhibitor clavulanic 
acid led to markedly reduced progressive periodontal attachment loss in patients with 
refractory chronic periodontitis heavily colonized by subgingival S. intermedius in the 
relative absence of gram-negative periodontal pathogens (30). However, Feres et al. (28) 
detected large transient increases in amoxicillin-resistant subgingival S. constellatus 
populations secondary to systemic amoxicillin therapy in patients with chronic perio-
dontitis, suggesting that there is likely some degree of non-ȕ-lactamase enzyme-based 
heterogeneity among United States periodontal S. constellatus strains in their sensitivity to 
amoxicillin. Further research is needed to evaluate the extent and molecular basis to which 
periodontal S. constellatus strains from various areas of the United States, as well as other 
geographic areas in the world, have amoxicillin susceptibility profiles which differ from 
our present study collection from the eastern United States.   
 
Clindamycin and azithromycin each displayed a relatively high level of in vitro anti-
microbial activity against subgingival S. constellatus and S. intermedius, with only a low 
proportion of drug-resistant strains identified in the present study. Clindamycin, in addition 
to its antimicrobial activity against S. intermedius, is also capable at sub-MIC concentra-
tions to markedly downregulate the organism’s extracellular release of intermedilysin, a 
cytolytic toxin that may contribute as a virulence factor in S. intermedius-associated 




In conclusion, subgingival isolates of S. constellatus and S. intermedius in vitro were all or 
nearly all susceptible to amoxicillin, clindamycin, and azithromycin, only intermediate in 
susceptibility to ciprofloxacin, frequently resistant to doxycycline, and nearly all resistant 
to metronidazole. Since subgingival S. constellatus and S. intermedius exhibit variable 
antibiotic susceptibility profiles, potentially complicating selection of periodontitis anti-
biotic therapy, microbiological analysis that encompasses antimicrobial sensitivity testing 
may be particularly helpful in periodontal treatment planning of species-positive patients 
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Purpose: Enterococcus faecalis may contribute to periodontal breakdown in heavily 
infected subgingival sites, particularly in patients responding poorly to mechanical forms of 
periodontal therapy. Because only limited data are available on the antimicrobial sensitivity 
of enterococci of subgingival origin, this study evaluated the in vitro antibiotic 
susceptibility of E. faecalis isolated from periodontitis patients in the United States. 
 
Materials and methods: Pure cultures of 47 subgingival E. faecalis clinical isolates were 
each inoculated onto specially prepared broth microdilution susceptibility panels containing 
vancomycin, teicoplanin, and six oral antibiotics of potential use in periodontal therapy. 
After incubation in ambient air for 18 to 20 hours, minimal inhibitory drug concentrations 
were determined using applicable Clinical and Laboratory Standards Institute criteria and 
interpretative guidelines. The organisms were additionally evaluated for in vitro resistance 
to metronidazole at 4 mg/L. 
       
Results: Periodontal E. faecalis exhibited substantial in vitro resistance to tetracycline 
(53.2% resistant), erythromycin (80.8% resistant or intermediate resistant), clindamycin 
(100% resistant to 2 mg/L), and metronidazole (100 % resistant to 4 mg/L). In comparison, 
the clinical isolates were generally sensitive to ciprofloxacin (89.4% susceptible; 10.6% 
intermediate resistant), and 100% susceptible in vitro to ampicillin, amoxicillin/clavulan-
ate, vancomycin, and teicoplanin.   
 
Conclusions: Tetracycline, erythromycin, clindamycin, and metronidazole revealed poor in 
vitro activity against human subgingival E. faecalis clinical isolates, and would likely be 
ineffective therapeutic agents against these species in periodontal pockets. Among orally-
administered antibiotics, ampicillin, amoxicillin/clavulanate, and ciprofloxacin exhibited 
marked in vitro inhibitory activity against periodontal E. faecalis, and may be clinically 













Enterococcus faecalis is a gram-positive, facultative coccus frequently implicated as an 
opportunistic pathogen in various types of nosocomial infections in immunocompromised 
patients (1). The organisms normally inhabit the gastrointestinal tracts of humans, farm 
animals, dogs, cats, ducks, and many types of insects, as well as environments contamin-
ated by human and animal feces (1,2). The alarming emergence in North America during 
the past 20 years of vancomycin-resistant E. faecalis and Enterococcus faecium strains (3), 
which are potentially multi-resistant to currently available antibiotics, has sparked increase-
ed clinical concerns about how best to treat and prevent human enterococcal infections (4).  
  
Enterococci appear to be absent or infrequently found on supragingival and subgingival 
tooth surfaces and mucosa in the healthy human oral cavity (5). When present, E. faecalis is 
most closely identified with persistent endodontic infections (6), possibly introduced into 
the oral microbiome via dietary consumption of certain types of aged cheese and other 
organism-positive food products (7,8).   
 
E. faecalis may opportunistically colonize periodontal pockets, and in some persons, may 
also contribute to periodontal breakdown in heavily infected sites (9-11). The organism has 
been recovered from the subgingival periodontitis microbiota (12-16), especially in patients 
responding poorly to mechanical forms of periodontal therapy (9,10). Persons positive for 
human immunodeficiency virus (HIV) infection (17), particularly those with necrotizing 
gingival lesions (11), also frequently yield periodontal E. faecalis. Because local and/or 
systemic antimicrobial therapy is increasingly employed on these types of periodontitis 
patients (18-20), and only limited data are available on the antimicrobial sensitivity of 
enterococci of subgingival origin (9,14,21,22), particularly from the United States (9), there 
is a need to further assess the antibiotic susceptibility of E. faecalis colonizing periodontal 
pockets to minimize clinical use and potential adverse effects of periodontal antimicrobial 
chemotherapy to which subgingival enterococci are resistant in organism-positive patients. 
As a result, this study evaluated the in vitro susceptibility of fresh subgingival E. faecalis 
clinical isolates, recovered from advanced chronic periodontitis patients in the United 
States, to various antibiotics of potential use in periodontal therapy.   
 
Materials and methods 
 
Patients and bacterial strains 
 
A total of 47 subgingival E. faecalis clinical isolates were recovered over a 12-month time 
period from 2,764 patient subgingival plaque specimens (1.7% E. faecalis-positive 
recovery rate) analyzed by the Oral Microbiology Testing Service (OMTS) Laboratory at 
Temple University School of Dentistry, Philadelphia, Pennsylvania. Each of the clinical 
isolates originated from one of 47 systemically healthy, non-hospitalized, adults (19 males 
and 28 females; aged 31 to 76 years; mean ± SD age: 55.2 ± 12.4 years) exhibiting 
advanced chronic periodontitis (23), as diagnosed by 27 periodontists in private dental 
practices in the United States, of which nearly all were geographically located in East Coast 





The E. faecalis clinical isolates were recovered from subgingival plaque specimens, 
obtained using a standardized sampling protocol, from 29 patients before periodontal 
therapy, and from 18 patients three to six months after the completion of conventional 
mechanical periodontal therapy when an unsatisfactory clinical outcome relative to 
resolution of inflamed deep probing depths was reported by the treating periodontist. None 
of the patients received any systemic antibiotic therapy within 3 months before subgingival 
sampling. After isolation with cotton rolls and removal of saliva and supragingival deposits, 
one to two sterile, absorbent paper points (Johnson & Johnson, East Windsor, NJ, USA) 
were advanced for approximately 10 seconds into each of the three to five deepest 
periodontal pockets (> 6 mm) per patient who exhibited bleeding on probing. After 
removal, all paper points per patient were pooled into a glass vial containing six to eight 
small glass beads and 2.0 ml of anaerobically prepared and stored VMGA III transport 
medium (24). The subgingival samples were then transported within 24 hours to the OMTS 
Laboratory, which is licensed for high-complexity bacteriologic analysis by the Pennsyl-
vania Department of Health. The OMTS Laboratory is also federally-certified by the 
United States Department of Health and Human Services to be in compliance with Clinical 
Laboratory Improvement Amendments-mandated proficiency testing, quality control, 
patient test management, personnel requirements, and quality-assurance standards required 
of clinical laboratories engaged in diagnostic testing of human specimens in the United 
States (25). All laboratory procedures were performed by personnel who were masked to 
the clinical status of the patients, and their inclusion in the present analysis. The study was 
approved by the Temple University Human Subjects Protections Institutional Review 
Board and conducted in accordance with the Helsinki Declaration of 1975, as revised in 
2000.         
 
At the OMTS Laboratory, the specimen vials were warmed to 35ºC to liquefy the VMGA 
III transport medium, and sampled microorganisms were mechanically dispersed from the 
paper points with a Vortex mixer at the maximal setting for 45 seconds. Serial 10-fold 
dilutions of the dispersed bacteria were prepared in Möller’s VMG I anaerobic dispersion 
solution (24), and appropriate 0.1 ml dilution aliquots were spread with a sterile bent glass 
rod onto non-selective enriched Brucella blood agar (EBBA) primary isolation plates (26), 
comprised of 4.3% Brucella agar supplemented with 0.3% bacto-agar, 5% defibrinated 
sheep blood, 0.2% hemolyzed sheep red blood cells, 0.0005% hemin, and 0.00005% 
menadione. Additional sample dilutions were inoculated onto EBBA primary isolation 
plates supplemented with metronidazole (Sigma-Aldrich, St. Louis, MO, USA) at 4 mg/L.  
All EEBA plates were incubated at 35qC for seven days in an anaerobic chamber (Coy 
Laboratory Products, Ann Arbor, MI, USA) containing 85% N2-10% H2-5% CO2.     
 
Periodontal E. faecalis was presumptively identified as relatively large (3.0-4.0 mm in 
diameter), shiny, gray-white, non-adherent, catalase-negative, flat, circular surface colonies 
with slightly irregular edges and variable hemolysis on anaerobically incubated EBBA (9).  
A micromethod kit system (RapID STR, Innovative Diagnostic Systems, Atlanta, GA, 
USA) was used to confirm E. faecalis clinical isolate identification and biotype, with 
preparation and inoculation of kit panels performed as recommended by the manufacturer.  
A nitrocefin-based qualitative chromogenic disk assay (BBL Cefinase, BD Diagnostic 
Systems, Sparks, MD, USA), following manufacturer’s instructions, was used to test the E. 
faecalis FOLQLFDO LVRODWHV IRU ȕ-lactamase enzyme activity. The proportional subgingival 
recovery of E. faecalis per organism-positive patient was determined by comparing their 
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colony forming units (CFU) among total viable anaerobic CFU counts on EBBA primary 
isolation plates.   
 
The occurrence and proportions of Aggregatibacter actinomycetemcomitans, Porphyro-
monas gingivalis, Parvimonas micra, Prevotella intermedia/nigrescens, Campylobacter 
rectus, Fusobacterium nucleatum, Streptococcus constellatus, gram-negative enteric rods/ 
pseudomonads, Staphylococcus aureus, and Candida species were also examined for in 
each patient’s pool of subgingival specimens to assess the distribution of co-infecting 
putative periodontal pathogens in E. faecalis-positive chronic periodontitis patients, using 
EBBA and selective culture media, incubation conditions, and presumptive phenotypic 
methods previously described (27-29). 
 
In vitro antimicrobial susceptibility testing 
 
The 47 E. faecalis clinical isolates were each grown in pure culture on EBBA incubated 
overnight in air plus 5% CO2, from which cell suspensions were prepared and adjusted to a 
5 x 105 organisms/ml density using a spectrophotometer with a 1.0 cm light path at 625 nm 
(0.08-0.10 absorbance range). The suspensions were then inoculated onto specially 
prepared broth microdilution susceptibility panels (Dade Microscan, West Sacramento, CA, 
USA), containing cation-adjusted Mueller-Hinton broth and the following antibiotics in 
two-fold concentration ranges: ampicillin (0.12 to 8 mg/L), amoxicillin/potassium 
clavulanate (0.5/0.25 to 16/8 mg/L), ciprofloxacin (0.25 to 2 mg/L), clindamycin (0.25 to 2 
mg/L), erythromycin (0.12 to 4 mg/L), teicoplanin (0.25 to 16 mg/L), tetracycline-HCl (2 to 
8 mg/L), and vancomycin (0.25 to 16 mg/L). High-level aminoglycoside resistance was 
evaluated in wells containing 2,000 mg/L of either gentamicin or streptomycin. S. aureus 
ATCC 29213 and E. faecalis ATCC 29212 were used as quality-control organisms.  
Minimal inhibitory concentrations (MIC), defined as the lowest antibiotic concentration 
that completely inhibited visible growth, were determined following panel incubation in 
ambient air at 35qC for 18 to 20 hours.     
 
In vitro resistance to metronidazole at 4 mg/L was recorded per patient when E. faecalis 
growth was noted on metronidazole-supplemented EBBA primary isolation plates 
(9,26,29,30). Bacteroides thetaiotaomicron ATCC 29741, Clostridium perfringens ATCC 
13124, and a multi-antibiotic-resistant clinical periodontal isolate of F. nucleatum were 
used as positive and negative quality controls for antibiotic resistance testing on 




MIC50 and MIC90 values for each antibiotic were determined as the MIC level that 
completely inhibited 50% and 90%, respectively, of the tested subgingival E. faecalis 
clinical isolates. MIC interpretative guidelines published in 2012 for Enterococcus species 
from the Clinical and Laboratory Standards Institute (CLSI) (31) were used to categorize 
test antibiotic in vitro inhibitory activity against the E. faecalis clinical isolates, except for 
clindamycin and metronidazole, where no applicable CLSI standards against enterococci 
are available. Ampicillin MIC interpretive criteria were applied to amoxicillin/clavulanate 







45 (95.7%) of the E. faecalis clinical isolates belonged to the same biotype, which were 
negative for hemolysin; fermented mannitol and sorbitol; hydrolyzed arginine, tyrosine, 
hydroxyproline, lysine, pyrrolidone, phosphatase and esculin; DQG HODERUDWHG Į-D-gluco-
VLGDVHĮ-D-galactosidase and N-acetyl-ȕ-D-glucosaminidase. Two other biotypes exhibited 
similar reactions, but one failed to hydrolyze hydroxyproline, and another was positive for 
KHPRO\VLQ DQG GLG QRW K\GURO\]H W\URVLQH DQG SKRVSKDWDVH 1R ȕ-lactamase enzyme 
activity was detected among the 47 E. faecalis clinical isolates with nitrocefin-based 
chromogenic testing.   
 
E. faecalis comprised a mean ± SE of 49.7 ± 4.0% (median, 55.4%; interquartile range, 
24.5 to 72.7%; total range, 1.1 to 95.2%) of total subgingival anaerobic viable counts in the 
47 organism-positive patients with advanced chronic periodontitis. E. faecalis was > 50% 
of the subgingival cultivable microbiota in 25 patients, from 10 to 50% in 20 patients, and 
< 10% in two patients. In 43 (91.5%) patients,  of the evaluated putative periodontal 
pathogens were detected in subgingival co-infection with E. faecalis, with P. gingivalis and 
P. micra most frequently recovered in the majority of patients with E. faecalis-positive 
chronic periodontitis (Table 1).    
 
Table 2 provides MIC50 and MIC90 values of test antimicrobial agents against subgingival 
E. faecalis. Teicoplanin and amoxicillin/clavulanate exhibited the lowest MIC90 values     
  DQG   PJ/ UHVSHFWLYHO\ ZKHUHDV WHWUDF\FOLQH-HCl displayed MIC90 
values which exceeded 8.0 mg/L against subgingival E. faecalis.      
 
Table 2 also lists the distribution of susceptible, intermediate, and resistant test results 
against E. faecalis clinical isolates for test antibiotics with available CLSI interpretive 
standards for enterococci. Substantial in vitro E. faecalis resistance was found to 
tetracycline-HCl (53.2% resistant) and erythromycin (80.8% resistant or intermediate 
resistant), with 19 (40.4%) of the clinical isolates jointly non-susceptible in vitro to both 
tetracycline-HCl and erythromycin. In comparison, subgingival E. faecalis was generally 
sensitive to ciprofloxacin, with 89.4% of the clinical isolates classified as susceptible and 
10.6% intermediate resistant (Table 2). All E. faecalis clinical isolates were 100% 
susceptible in vitro to ampicillin, amoxicillin/clavulanate, vancomycin, and teicoplanin, 
according to CLSI MIC interpretative guidelines (Table 2).   
 
In addition, all E. faecalis clinical isolates were resistant in vitro to clindamycin at 2 mg/L 
and metronidazole at 4 mg/L. High-level aminoglycoside resistance was rare among sub-
gingival E. faecalis, with only three (6.0%) clinical isolates demonstrating in vitro resis-
tance to streptomycin at 2,000 mg/L, and none to gentamicin at 2,000 mg/L. The single 
hemolysin-positive E. faecalis clinical isolate was resistant in vitro to tetracycline-HCl, 





























































































   
   
   
   










































































































































































































































































































































































































































































































   
   
   
   






























































































































































































































































































































Relatively sparse data are available on the antibiotic sensitivity profile of subgingival 
enterococci. Rams et al. (9) reported in 1992 on the in vitro antibiotic susceptibility of 12 
subgingival E. faecalis clinical isolates from United States periodontitis patients, and more 
recently, 23 to 106 subgingival E. faecalis strains were assessed from periodontitis patients 
in Norway (14,21,22). However, because antibiotic resistance patterns of E. faecalis, and 
subgingival bacterial species in particular, potentially change over time (3,4,32), and 
exhibit geographic-based differences (30,33,34), these previous studies of subgingival E. 
faecalis conducted 20 years ago (9) or in Europe (14,21,22) may not necessarily be 
pertinent to contemporary clinical periodontal practice in the United States. This study 
tested the in vitro antibiotic susceptibility of the largest group of subgingival E. faecalis 
clinical isolates (n = 47) assembled to date from periodontitis patients of United States 
origin.   
 
Importantly, vancomycin resistance was not detected among United States subgingival E. 
faecalis clinical isolates. Because vancomycin resistance was also not found in periodontal 
E. faecalis in Norway (14,21,22), and E. faecalis recovered from root canals (35-39) and 
oral rinse/saliva/intraoral surface samples (40-41), it appears that the human oral cavity in 
community-dwelling dental patients is not a significant reservoir for carriage and potential 
dissemination of vancomycin-resistant E. faecalis. The occurrence of vancomycin-resistant 
E. faecalis, as well as the resistance of the organism to other antimicrobial agents, such as 
ciprofloxacin, are markedly higher and concentrated in clinical infection isolates from 
hospitalized patients compared to non-hospitalized, community population groups (34).  
 
Tetracycline-HCl, erythromycin, clindamycin, and metronidazole were found to exert rela-
tively poor in vitro activity against subgingival E. faecalis, similar to previous evaluations 
of other periodontal and intraoral E. faecalis strains (14,21,22,35-42). Although clinda-
mycin and metronidazole may be used in periodontal therapy (18-20), in vitro clindamycin 
and metronidazole resistance among facultative E. faecalis was expected since the 
organism is intrinsically resistant to clindamycin, and metronidazole possesses an 
antimicrobial spectrum limited to anaerobic bacteria and protozoa (43). As a result, these 
drugs, as well as tetracycline-HCl and erythromycin, would likely be ineffective thera-
peutic agents against E. faecalis in periodontal pockets, and may even be contraindicated in 
patients with heavy subgingival enterococcal colonization in order to reduce the risk of 
post-drug emergence of potentially-adverse E. faecalis superinfections by resistant strains.  
In contrast, all subgingival E. faecalis ZHUHQHJDWLYHIRUȕ-lactamase enzyme activity in the 
present study, similar to previous reports on oral E. faecalis strains (36,42), and all were 
susceptible in vitro to both ampicillin and amoxicillin/clavulanate at therapeutically attain-
able concentrations, also consistent with previous studies of periodontal and intraoral E. 
faecalis strains (14,21,22,35-42).     
 
It is important to note that generally high subgingival proportions (mean: 49.7% of total 
subgingival viable count) of E. faecalis were recovered from the organism-positive 
patients, with most (91.5%) yielding E. faecalis as part of a mixed polymicrobial infection 
in deep periodontal pockets with various putative periodontal pathogens, most notably P. 
gingivalis and P. micra (Table 1). The occurrence and proportions of subgingival co-




been previously reported and may help illuminate potential disease-associated subgingival 
microbial interactions, because the pathogenicity of E. faecalis is enhanced in experimental 
subcutaneous mice abscess formation via co-infection with P. micra (44).  
  
Little attention has been given to potential therapeutic implications of heavy E. faecalis 
growth in periodontal pockets concurrent with large numbers of anaerobic periodontal 
pathogens, particularly in periodontitis patients refractory to mechanical forms of 
periodontal therapy (9,10). Colombo et al. (10) found subgingival E. faecalis and anaerobic 
periodontal pathogens in three of 14 (21.4%) periodontitis patients experiencing wide-
spread progressive clinical periodontal attachment loss within 12 months after treatment 
with subgingival mechanical debridement, modified Widman flap surgery, systemic 
tetracycline-HCl therapy, and systematic three-month periodontal maintenance care. 
Refractory periodontitis patients also revealed high serum antibody titers to E. faecalis and 
several anaerobic periodontal pathogens, likely reflective of their oral colonization, more 
often as compared to successfully treated periodontitis patients and periodontally healthy 
subjects (45). High E. faecalis counts additionally have been detected with anaerobic 
periodontal pathogens in active necrotizing gingivitis/periodontitis lesions in HIV-positive 
individuals (11). E. faecalis can participate in biofilm formation on non-shedding surfaces 
(21,22), appears to be inadequately suppressed by subgingival mechanical debridement 
therapy (9,10), and may inactivate metronidazole drug regimens targeted against anaerobic 
bacterial pathogens (46,47). In turn, a number of anaerobic periodontal pathogens may 
elaborate ȕ-ODFWDPDVH HQ]\PHV  ZKLFK KDYH WKH SRWHQWLDO WR LQDFWLYDWH ȕ-lactam 
antibiotics that otherwise would likely be active against subgingival E. faecalis. Thus, 
subgingival co-infection by high proportions of metronidazole-inactivating E. faecalis, 
aORQJZLWKȕ-lactamase producing anaerobic periodontal pathogens, may potentially resist 
amoxicillin plus metronidazole combination drug regimens frequently recommended for 
refractory periodontitis (18-20). In these situations, which appear to be infrequent given the 
low occurrence of subgingival enterococci in United States patients with periodontitis (9), 
metronidazole may be better paired with amoxicillin/clavulanate, which competitively 
LQKLELWV ȕ-lactamase enzymes (50), or alternatively with ciprofloxacin, if in vitro testing 
reveals the enterococci to be ciprofloxacin susceptible, and a review of the patient’s 
medical history and current medications indicate that the antibiotic drugs can be safely 
administered. With all antimicrobial regimens, subgingival mechanical debridement 
immediately before or concurrent with antimicrobial chemotherapy appears essential with 
E. faecalis periodontal infections, because the organism in undisturbed surface biofilms 
compared to dispersed planktonic phase cells exhibits markedly enhanced antibiotic 
resistance (21), similar to biofilms formed by other subgingival microbial species (51,52).  
Because no consensus presently exists on optimal management of patients with refractory 
periodontitis presenting with mixed enterococci-anaerobic periodontal pathogen sub-
gingival biofilm populations, additional clarifying clinical studies on these potentially 




Tetracycline-HCl, erythromycin, clindamycin, and metronidazole revealed poor in vitro 
activity against human subgingival E. faecalis clinical isolates and, thus, would likely be 
ineffective therapeutic agents against these species in periodontal pockets. Among orally 
administered antibiotics, ampicillin, amoxicillin/clavulanate, and ciprofloxacin exhibited 
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marked in vitro inhibitory activity against all or most periodontal E. faecalis and may be 
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Purpose: ȕ-lactam antibiotics prescribed in periodontal therapy are vulnerable to 
GHJUDGDWLRQE\EDFWHULDO ȕ-ODFWDPDVH HQ]\PHV7KLV VWXG\ HYDOXDWHG WKHRFFXUUHQFHRIȕ-
lactamase enzyme-positive subgingival bacteria in chronic periodontitis subjects of USA 
origin, and assessed their in vitro resistance to metronidazole at a breakpoint concentration 
of 4 mg/L.   
 
Materials and methods: Subgingival plaque specimens from deep periodontal pockets 
with bleeding on probing were removed from 564 adults with severe chronic periodontitis 
before treatment. The samples were transported in VMGA III, and then plated onto: (i) non-
selective enriched Brucella blood agar (EBBA) and incubated anaerobically for seven days; 
and (ii) selective trypticase soy-bacitracin-vancomycin (TSBV) and incubated for three 
days in air + 5% CO2. At the end of the incubation periods, the bacterial test species were 
identified and quantified. Specimen dilutions were also plated onto EBBA plates 
supplemented with 2 mg/L of amoxicillin, a combination of 2 mg/L of amoxicillin plus 2 
PJ/RIWKHȕ-lactamase inhibitor clavulanic acid, or 4 mg/L of metronidazole, followed by 
DQDHURELF LQFXEDWLRQ IRU VHYHQ GD\V %DFWHULDO WHVW VSHFLHV SUHVXPSWLYHO\ SRVLWLYH IRU ȕ-
lactamase production were identified by growth on EBBA primary isolation plates 
supplemented with amoxicillin alone and no growth on EBBA primary isolation plates 
containing both amoxicillin plus clavulanic acid. A subset of such isolates was subjected to 
nitrocefin-based chromogenic disk testing to coQILUPSUHVHQFHRIȕ-lactamase activity. In 
vitro resistance to 4 mg/L of metronidazole was noted when growth of test species occurred 
on metronidazole-supplemented EBBA culture plates.   
        
Results:   RI WKH VWXG\ VXEMHFWV \LHOGHG ȕ-lactamase-producing subgingival 
bacterial test species, with Prevotella intermedia/nigrescens, Fusobacterium nucleatum and 
other Prevotella VSHFLHV PRVW IUHTXHQWO\ LGHQWLILHG DV ȕ-lactamase-producing organisms.  
2IWKHȕ-lactamase-producing bacterial test species strains recovered, 98.9% were suscepti-
ble in vitro to metronidazole at 4 mg/L.  
 
Conclusions: 7KHRFFXUUHQFHRIȕ-lactamase-positive subgingival bacterial species in more 
than half of the subjects with severe chronic periodontitis raises questions about the 
therapeutic potential of single-GUXJ UHJLPHQV ZLWK ȕ-lactam antibiotics in periodontal 
therapy. The in vitro HIIHFWLYHQHVV RI PHWURQLGD]ROH DJDLQVW QHDUO\ DOO UHFRYHUHG ȕ-
lactamase-producing subgingival bacterial species further supports clinical periodontitis 







ȕ-lactamase production represents a major virulence factor by which pathogenic bacteria 
evade the broad-VSHFWUXP DQWLPLFURELDO HIIHFWV RI ȕ-lactam antibiotics and perpetuate 
KXPDQ LQIHFWLRQV LQFOXGLQJ WKRVH LQ RURIDFLDO WLVVXHV  %DFWHULDO ȕ-lactamases rapidly 
hydrolyze amide bonds within the four-membered ring forming the foundational structure 
RI ȕ-lactam antibiotics, leaving them pharmacologically inactive as antimicrobial agents 
that disrupt bacterial cell wall peptidoglycan biosynthesis (1).  
 
ȕ-lactamase activity has been detected in subgingival sites of chronic periodontitis subjects 
DW OHYHOV FDSDEOH RI LQDFWLYDWLQJ ȕ-lactam antibiotics passing into periodontal pockets 
WKURXJK JLQJLYDO FUHYLFXODU IOXLG H[XGDWH  6XEJLQJLYDO ȕ-lactamase has been signifi-
cantly correlated with increasing periodontal probing depth measurements (2), recent 
WUHDWPHQWZLWKV\VWHPLFSHQLFLOOLQGUXJVDQGFDUULDJHRIȕ-lactamase-encoding genes by 
microbial species in subgingival plaque biofilms (4). Studies of patients with chronic 
periodontitis in the USA (3-5), The Netherlands (6,7), Spain (7), Norway (8), France (9,10), 
and the United Kingdom (11) have reported a 53.2% to 100% occurrence in subjects for 
VXEJLQJLYDOȕ-lactamase-producing bacteria, with higher prevalence rates found in localities 
with greater over-the-counter access and consumption of systemic antimicrobial agents (7). 
However, these findings are limited by their inclusion of relatively few study subjects (12 
to 47 patients with periodontitis per study), who were mostly dental school patients and/or 
from localized geographic regions that may not be representative of more diverse 
community populations. For example, data from the USA on the occurrence of subgingival 
ȕ-lactamase-producing bacterial species in patients with chronic periodontitis is presently 
derived from a total of 42 dental school patients in Connecticut, and 25 in Florida (3,5). 
 
$VDUHVXOWWKHUHLVDQHHGWRDVVHVVVXEJLQJLYDOȕ-lactamase-producing bacteria in larger-
sized subject groups that are geographically distributed beyond a single city or dental 
VFKRROSDWLHQWSRSXODWLRQ7KHDLPRIWKHSUHVHQWVWXG\ZDVWRHYDOXDWHWKHRFFXUUHQFHRIȕ-
lactamase-positive subgingival bacteria in 564 geographically subjects in the USA with 
chronic periodontitis, and to assess their in vitro resistance to metronidazole at a breakpoint 
concentration of 4 mg/L.       
 




A total of 564 adults (270 men and 294 women; age range, 33-91 years; mean age ± 
standard deviation = 49.1 ± 11.7 years), diagnosed with severe chronic periodontitis (12) by 
periodontists in private dental practices in the USA, were included in the present study as 
their subgingival plaque samples were consecutively received for microbiological analysis 
by the Oral Microbiology Testing Service (OMTS) Laboratory at Temple University 
School of Dentistry, Philadelphia (PA, USA). 354 (62.8%) of the study subjects 
geographically originated from Maryland (n = 174), Pennsylvania (n = 91), New Jersey (n 
= 51), Delaware (n = 25), Virginia (n = 7), and the District of Columbia (n = 6) in the mid-
Atlantic region of the USA, with all others from Connecticut (n = 48), Florida (n = 35), 
Illinois (n = 20), 11 other states in the eastern USA (n = 47) and Texas (n = 60). Persons 




excluded. Approval for the study was provided by the Temple University Human Subjects 
Protections Institutional Review Board.    
 
Microbial sampling and transport 
 
Subgingival plaque specimens were obtained by the diagnosing periodontists, who 
IROORZHGD VWDQGDUGL]HGVDPSOLQJSURWRFROEHIRUH WUHDWPHQW IURP WKUHH WR ILYHGHHS 
mm) periodontal pockets in each subject that exhibited bleeding on probing during the 
initial diagnostic evaluation. After isolation with cotton rolls, and removal of saliva and 
supragingival deposits, one to two sterile, absorbent paper points (Johnson & Johnson, East 
Windsor, NJ, USA) were advanced into each selected periodontal site for approximately 10 
seconds. Upon removal, all paper points per study subject were pooled in a glass vial 
containing six to eight small glass beads and 2.0 ml of anaerobically prepared and stored 
VMGA III transport medium (13), which possesses a high preservation capability for oral 
microorganisms during post-sampling transit to the laboratory (13,14). The subgingival 
samples were then transported within 24 hours to the OMTS Laboratory, which is licensed 
for high-complexity bacteriological analysis by the Pennsylvania Department of Health.  
The OMTS Laboratory is also federally certified by the United States Department of Health 
and Human Services to be in compliance with Clinical Laboratory Improvement 
Amendments-mandated proficiency testing, quality control, patient test management, 
personnel requirements and quality assurance standards required of clinical laboratories 
engaged in diagnostic testing of human specimens in the USA (15). All laboratory 
procedures were performed by personnel who were blinded to the clinical status of the 
study subjects and their inclusion in the present analysis. 
 
Microbial culture and incubation  
 
At the OMTS Laboratory, the specimen vials were warmed to 35ºC to liquefy the VMGA 
III transport medium, and sampled microorganisms were mechanically dispersed from the 
paper points with a vortex mixer, which was used at the maximal setting for 45 seconds.  
Serial, 10-fold dilutions of the dispersed bacteria were prepared in Möller’s VMG I 
anaerobic dispersion solution, comprised of prereduced, anaerobically sterilized, 0.25% 
tryptose, 0.25% thiotone E peptone, and 0.5% NaCl (13). Then, 0.1 ml dilution aliquots 
were spread, with a sterile bent glass rod, onto nonselective enriched Brucella blood agar 
(EBBA) primary isolation plates (16), comprised of 4.3% Brucella agar supplemented with 
0.3% bacto-agar, 5% defibrinated sheep blood, 0.2% hemolyzed sheep red blood cells, 
0.0005% hemin and 0.00005% menadione, and onto selective trypticase soy-bacitracin-
vancomycin (TSBV) agar (17). The inoculated EBBA plates were incubated at 35ºC for 
seven days in a Coy anaerobic chamber (Coy Laboratory Products, Ann Arbor, MI, USA) 
containing 85% N2, 10% H2 and 5% CO2, and the TSBV plates were incubated at 35ºC for 
three days in air + 5% CO2. 
 
Test species identification 
 
Total anaerobic viable counts, and counts of the test species Porphyromonas gingivalis, 
Prevotella intermedia/nigrescens, other Prevotella species (including Prevotella melanin-
ogenica and non-pigmented Prevotella species), Fusobacterium nucleatum, Parvimonas 




coccus faecalis, and staphylococci, were made on non-selective EBBA primary isolation 
plates using a ring-light magnifying loupe, presumptive phenotypic methods previously 
described (18-21), and the RapID ANA II (Innovative Diagnostic Systems, Atlanta, GA, 
USA) micro-method kit system for selected isolates. Aggregatibacter actinomycetem-
comitans, gram-negative enteric rods/pseudomonads, and Candida species were quantitated 
on selective TSBV agar, as previously described (16,17). The proportional recovery of each 
test species was ascertained in each subject by calculating as the percentage of each test 
species colony-forming units relative to total subgingival anaerobic viable counts, as 




Additional 0.1 ml aliquots of subgingival sample dilutions were inoculated onto EBBA 
primary isolation plates supplemented with either 2 mg/L of amoxicillin, which was 
previously established as a susceptibility breakpoint for aminopenicillin antibiotics (22), or 
D FRPELQDWLRQ RI  PJ/ RI DPR[LFLOOLQ SOXV  PJ/ RI WKH ȕ-lactamase-inhibitor, 
clavulanic acid (23), followed by anaerobic incubation. Direct colony suspensions 
(equivalent to a 0.5 McFarland standard) of pure A. actinomycetemcomitans isolates from 
selective TSBV were subcultured onto these media as their recognition is frequently 
obscured within mixed bacterial populations on non-selective EBBA primary isolation 
plates (17).    
 
A surface-overlay technique was used to add clavulanic acid, at a concentration of 2 mg/L, 
to amoxicillin-containing EBBA primary isolation plates (24). Using a sterile glass rod, 0.1 
ml of a fresh 400 mg/L solution of clavulanic acid, prepared by dissolving 4.2 mg of a 
95.3% pure lithium clavulanate powder (provided by SmithKline Beecham, Collegeville, 
PA, USA) into 10 ml of sterile 0.1 M phosphate buffer (pH 6.0), was evenly spread over 
the surfaces of 20 ml EBBA plates supplemented with amoxicillin. The plates were held at 
room temperature for 30 minutes to allow surface drying and subsurface drug diffusion, and 
then inoculated with subgingival plaque specimens.   
 
7HVWVSHFLHVSRVLWLYHIRUȕ-lactamase production were presumptively identified by growth 
on EBBA primary isolation plates supplemented with amoxicillin alone and by no growth 
on EBBA primary isolation plates containing both amoxicillin plus clavulanic acid (6,7).  A 
subset of 50 such presumptively identified isolates was subjected to a nitrocefin-based 
qualitative chromogenic disk assay (BBL Cefinase; BD Diagnostic Systems, Sparks, MD, 
86$IROORZLQJPDQXIDFWXUHU¶VLQVWUXFWLRQVWRFRQILUPSUHVHQFHRIȕ-lactamase activity. 
 
In vitro antibiotic resistance testing 
 
Aliquots (0.1 ml) of subgingival sample dilutions were also inoculated onto EBBA primary 
isolation plates supplemented with metronidazole at a susceptibility breakpoint 
concentration of 4 mg/L (22), and incubated anaerobically for seven days, in order to assess 
in vitro UHVLVWDQFHWRPHWURQLGD]ROHDPRQJȕ-lactamase-producing clinical isolates. In vitro 
resistance to metronidazole was defined as test species growth on metronidazole-
supplemented EBBA primary isolation plates (16,20,25,26). Bacteroides thetaiotaomicron 
ATCC 29741, Clostridium perfringens ATCC 13124 and a multi-antibiotic-resistant clin-




controls for the antibiotic resistance testing. All antimicrobials were obtained as pure 




Descriptive analysis were used to calculate mean subject age and standard deviation values, 
the occurrence and proportional cultivable recovery of test species in subjects, the 
RFFXUUHQFHDQGSURSRUWLRQDOUHFRYHU\RIȕ-lactamase-producing organisms in subjects, and 
the occurrence in subjects of in vitro metronidazole drug resistance among the subgingival 
clinical isolates. Data analysis was performed using the SAS 9.2 for Windows (SAS 




$ VXEVHW RI  WHVW VSHFLHV SUHVXPSWLYHO\ LGHQWLILHG DV ȕ-lactamase positive by their 
growth on amoxicillin-supplemented EBBA primary isolation plates and by no growth on 
amoxicillin plus clavulanic acid-supplemented EBBA primary isolation plates, were all 
FRQILUPHGDVȕ-lactamase-producing organisms with the nitrocefin chromogenic disk assay 
(data not shown).  
 
$ WRWDO RI   VWXG\ VXEMHFWV \LHOGHG ȕ-lactamase-producing subgingival test 
species. P. intermedia/nigrescens, F. nucleatum, and other Prevotella species were most 
IUHTXHQWO\LGHQWLILHGDVȕ-lactamase-positive species, with 51.0% of all study subjects with 
cultivable P. intermedia/nigrescens, 24.6% with F. nucleatum and 66.2% with other 
Prevotella VSHFLHVH[KLELWLQJȕ-lactamase-producing stUDLQVRI WKHVH VSHFLHV 7DEOHȕ-
lactamase production was also found among 0.8% of P. micra species, 2.0% of Capno-
cytophaga species and 5.0% of gram-negative enteric rods/pseudomonads in culture-
positive subjects (Table 1).  
 
$VLQJOHȕ-lactamase-producing subgingival test species was recovered from 236 (80.3%) 
subjects, whereas 54 (18.4%) and four (1.3%) subjects each yielded two and three different 
ȕ-lactamase-producing test species, respectively (Figure 1).   
 
6XEJLQJLYDO SURSRUWLRQV RI ȕ-lactamase-positive P. intermedia/nigrescens, F. nucleatum 
and P. micra averaged 6.7-9.9%, whereas mean subgingival recovery levels of < 1% were 
IRXQGIRUȕ-lactamase-positive isolates of other Prevotella and for Capnocytophaga species 
(Table 1). 353 (98.9%) of the 35 ȕ-lactamase-producing subject test species recovered 
(Table 1) were susceptible in vitro to 4 mg/L of metronidazole, except for one P. inter-
media/nigrescens strain, one F. nucleatum strain, and gram-negative enteric rods/pseudo-
monads in two subjects.   
 
All recovered strains of P. gingivalis, A. actinomycetemcomitans, S. constellatus, C. 
periodontii, E. faecalis, and Staphylococcus VSHFLHVIDLOHG WRGHPRQVWUDWHSUHVXPSWLYHȕ-








































































































































































































































































































































































































































































































































































































































   
   
   
   





























                                 
)LJXUH2FFXUUHQFHRIRQHRUPRUHSHULRGRQWDOEDFWHULDOSDWKRJHQVSURGXFLQJȕ-lactamase  







ducing bacteria to be present in a majority of patients with chronic periodontitis (3-11).  A 
strength of the present study is that it assessed the largest group, to date, of subjects with 
FKURQLF SHULRGRQWLWLV IRU VXEJLQJLYDO ȕ-lactamase-producing bacteria (n = 564); similar, 
previous, investigations have collectively examined a total of only 255 subjects with 
chronic periodontitis (3,5-11). The present study data also evaluated a private dental 
practice-based convenience sample of subjects with chronic periodontitis originating from a 
ZLGHUJHRJUDSKLFUHJLRQWKDQLQSUHYLRXVUHSRUWVIURPWKH86$RQVXEJLQJLYDOȕ-lactamase 
activity (2,3,5), which may permit the findings to be more generalizable to a broader range 
of USA community population groups.  
 
Owning to the instability of clavulanic acid in agar dilution plates stored for more than 
three days (24), a surface-overlay technique was used in this study to add clavulanic acid to 
amoxicillin-containing EBBA primary isolation plates immediately before in vitro testing.  
6LQFHFODYXODQLFDFLGELQGV LUUHYHUVLEO\ WRȕ-lactamase enzymes and prevents inactivation 
RIȕ-lactam antibiotics (23), microbial growth patterns on these plates were compared with 
those on EBBA plates supplemented with amoxicillin only as a presumptive method for 
GHWHFWLQJ ȕ-lactamase-positive subgingival bacterial species. This approach was validated 
ZLWK FRQILUPDWRU\ QLWURFHILQ FKURPRJHQLF GLVN WHVWLQJ IRU ȕ-lactamase activity from 
presumptively detected subgingival bacterial species in previous studies (6,7), as well as on 
a subset of such subject isolates in the present study. 
 
,Q WKLV VWXG\ RI VXEMHFWVZLWK XQWUHDWHG FKURQLF SHULRGRQWLWLV \LHOGHG ȕ-lactamase 
producing subgingival bacteria, which is at the lower end of the prevalence rates of 53.2% 
to 100% reported in previous studies (3,5-11). This may be because of differences in 
periodontal disease severity, treatment status, and recent systemic antibiotic usage among 
the evaluated subjects with chronic periodontitis, and the microbiological methods 
employed. For example, some previous studies evaluated only subjects with “refractory” 
chronic periodontitis, responding poorly to conventional mechanical periodontal therapy 
(5,8). As systemic antimicrobial therapy is frequently employed in such patients (27), 
ZKLFKLVSRVLWLYHO\FRUUHODWHGZLWKLQFUHDVHGVXEJLQJLYDOȕ-lactamase activity (3), it is not 
VXUSULVLQJ WKDW D JUHDWHU RFFXUUHQFHRI ȕ-lactamase-producing subgingival bacteria would 
be reported for patients with “refractory” periodontitis compared with patients with 
untreated chronic periodontitis without antibiotic use within the past six months, as in the 
SUHVHQW VWXG\ ,Q WKLV UHJDUG WKHRFFXUUHQFHRI VXEJLQJLYDOȕ-lactamase-producing 
bacteria in the present study is similar to the 48% rate documented among 21 patients with 
chronic periodontitis not exposed to antibiotic therapy over the previous 12 months (3).  
0RUHRYHUDKLJKHURFFXUUHQFHRIVXEJLQJLYDOȕ-lactamase would also be expected among 
subjects with chronic periodontitis from countries, such as in southern Europe, with greater 
antibiotic over-the-counter access and consumption rates than found in the USA (28).   
 
P. intermedia/nigrescens, F. nucleatum, and other Prevotella species were the most fre-
quently LGHQWLILHG ȕ-lactamase-positive species in the present study, consistent with pre-
vious investigations (3,5-10). Subgingival recovery of cultivable enzyme-producing strains 
of P. intermedia/nigrescens and F. nucleatum averaged 9.6% and 6.7%, respectively, of 




species occurred in lower proportions, averaging < 1%. P. micra, Capnocytophaga species, 
and gram-QHJDWLYHHQWHULFURGVSVHXGRPRQDGVZHUHDOVRIRXQGWREHȕ-lactamase positive 
in some study subjects. Interestingly, all 197 strains of P. gingivalis in subjects in the 
SUHVHQWVWXG\ZHUHȕ-lactamase negative, in agreement with most previous studies of sub-
gingival isolates (6,9,29). In contrast, 7.7% of 26 subgingival P. gingivalis strains were 
UHSRUWHG ȕ-lactamase-positive in one study (30), and 25.5% of 51 strains in another (31) 
were found in vitro to be resistant to amoxicillin, but susceptible to amoxicillin/clavulanic 
DFLG LQGLFDWLYH RI ȕ-lactamase production. AddLWLRQDO ȕ-lactamase positive microbial 
species and subjects would likely be identified with more sensitive methods, such as 
PROHFXODUDQDO\VLVRIEDFWHULDO6ULERVRPDO51$JHQHVHTXHQFHVRUȕ-lactamase-
encoding genes (4,10,32,33), than the culture-based procedures employed in the present 
study.      
 
7KLV VWXG\ DOVR GLG QRW FODVVLI\ ȕ-ODFWDPDVH SKHQRW\SHV WHVW IRU ȕ-lactamase groups 
UHVLVWDQW WR FODYXODQLF DFLG RU TXDQWLWDWH WKH VWUHQJWK RI VXEJLQJLYDO ȕ-lactamase activity 
SUHVHQW LQ ȕ-lactamase-positive subjects (1,2). Additionally, the private practice perio-
dontists who diagnosed the study subjects were not calibrated in their assessments, 
although support for their diagnosis of severe chronic periodontitis was evidenced by their 
identification for microbiological sampling of three or more periodontal sites per subject 
ZLWKSURELQJGHSWKVPPZKLFK VWURQJO\FRUUHODWHV SRVLWLYHSUHGLFWLYHYDOXH
with the presence of severe periodontal attachment loss in adults (34). 
 
7KH SUHVHQFH RI ȕ-lactamase activity in periodontal pockets poses potentially important 
therapeutic implications relative to control of mixed populations of subgingival periodontal 
EDFWHULDO SDWKRJHQV LQ GHQWDO SODTXH ELRILOPV (Q]\PDWLF GHJUDGDWLRQ RI ȕ-lactam anti-
biotics PD\ SHUPLW VXEJLQJLYDO SHUSHWXDWLRQ RI ȕ-lactamase-producing microbial species 
and other organisms in the subgingival microbiota that otherwise would be suppressed by 
ȕ-ODFWDP DQWLELRWLFV  $Q LQFUHDVLQJ SUHYDOHQFH RI ȕ-lactamase activity among oral 
bacterial isolates has been reported (35), which is largely thought to be the result of plasmid 
and transposon-PHGLDWHG FRQMXJDO WUDQVIHU DQG GLVVHPLQDWLRQ RI ȕ-lactamase-encoding 
JHQHV DPRQJ PLFURRUJDQLVPV VXUYLYLQJ IROORZLQJ VHOHFWLYH SUHVVXUH E\ ȕ-lactam 
aQWLELRWLFVȕ-lactamases may predispose systemic penicillin monotherapy, unprotected 
E\ ȕ-lactamase-inhibitors, to oral cavity treatment failures, such as recalcitrant orofacial 
infections (36,37) and periodontal surgical flap necrosis (38), as well as enhance perio-
dontal abscess risk in untreated periodontitis subjects (39,40).  
 
Penicillin and amoxicillin are among systemic antibiotics most frequently prescribed by 
periodontists (41). However, relatively little research attention has been given to their 
DGMXQFWLYHXVHLQSHULRGRQWDOWKHUDS\LQWKHDEVHQFHRIȕ-lactamase inhibitors (42,43), with 
systemic phenoxymethyl penicillin failing to provide significant treatment benefits in a 
clinical trial of patients with aggressive periodontitis (44). It is noteworthy that subgingival 
bacterial isolates resistant to 2 mg/L of amoxicillin were found to show a transient increase 
from a pre-treatment baseline of 0.5% to 35% (a 70-fold increase), over the course of an 
adjunctive 14-day systemic amoxicillin drug regimen, in patients with chronic periodontitis 
(45). In that study, P. intermedia/nigrescens and P. melaninogenicaRIWHQLGHQWLILHGDVȕ-
lactamase-producing species in the present and previous studies (3,5-10), were found to be 




HULDO ȕ-lactamase activity contributed to these in vivo microbiological shifts was not ad-
dressed in the study, and remains to be delineated in future investigations.      
  
Finally, the present sWXG\ IRXQG  RI UHFRYHUHG VXEJLQJLYDO ȕ-lactamase-producing 
bacteria to be susceptible in vitro to 4 mg/L of metronidazole, an observation consistent 
ZLWKSUHYLRXVUHSRUWV $VD UHVXOWPHWURQLGD]ROHVXSSUHVVLRQRIȕ-lactamase-posi-
tive microbial species may, in part, help protect concurrently administered amoxicillin from 
in vivo GHJUDGDWLRQ E\ EDFWHULDO ȕ-lactamases, better enabling pharmacologically active 
amoxicillin to reach penicillin-binding proteins on bacterial cell membranes to exert 
antimicrobial effects (1), and contributing to the documented clinical and microbiological 
benefits of systemic amoxicillin plus metronidazole in periodontal therapy (46-49).  
However, this may not occur in patients from certain geographic regions, such as in 
Columbia, where marked in vitro PHWURQLGD]ROH UHVLVWDQFH PD\ EH IRXQG DPRQJ ȕ-
lactamase-positive subgingival isolates of P. gingivalis, P. intermedia/nigrescens, P. me-




,QFRQFOXVLRQWKHRFFXUUHQFHRIȕ-lactamase-positive subgingival bacterial species in more 
than one-half of subjects with severe chronic periodontitis raises questions about the 
therapeutic potential of single-GUXJ UHJLPHQV ZLWK ȕ-lactam antibiotics in periodontal 
therapy. The in vitro HIIHFWLYHQHVV RI PHWURQLGD]ROH DJDLQVW QHDUO\ DOO UHFRYHUHG ȕ-
lactamase-producing subgingival bacterial species further supports clinical periodontitis 
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Purpose: Chronic periodontitis patients may yield multiple species of putative periodontal 
bacterial pathogens that vary in their antibiotic drug susceptibility. This study determined 
the occurrence of in vitro antibiotic resistance among selected subgingival periodontal 
pathogens in chronic periodontitis patients. 
 
Materials and methods: Subgingival biofilm specimens from inflamed deep periodontal 
pockets were removed prior to treatment from 400 adults in the United States with chronic 
periodontitis. The samples were cultured, and selected periodontal pathogens tested in vitro 
for susceptibility to amoxicillin at 8 mg/L, clindamycin at 4 mg/L, doxycycline at 4 mg/L, 
and metronidazole at 16 mg/L, with a post-hoc combination of data for amoxicillin and 
metronidazole. Gram-negative enteric rods/pseudomonads were subjected to ciprofloxacin 
disk diffusion testing.       
        
Results: Overall, 74.2% of the periodontitis patients revealed subgingival periodontal 
pathogens resistant to at least one of the test antibiotics. One or more test species, most 
often Prevotella intermedia/nigrescens, Streptococcus constellatus or Aggregatibacter 
actinomycetemcomitans, were resistant in vitro to doxycycline, amoxicillin, metronidazole, 
or clindamycin, in 55%, 43.3%, 30.3%, and 26.5% of the chronic periodontitis patients, 
respectively. 15% of patients harbored subgingival periodontal pathogens resistant to both 
amoxicillin and metronidazole, which were mostly either S. constellatus (45 persons) or 
ciprofloxacin-susceptible strains of gram-negative enteric rods/pseudomonads (nine per-
sons).   
 
Conclusions: Chronic periodontitis patients in the United States frequently yielded 
subgingival periodontal pathogens resistant in vitro to therapeutic concentrations of 
antibiotics commonly utilized in clinical periodontal practice. The wide variability found in 
periodontal pathogen antibiotic resistance patterns should concern clinicians empirically 
selecting antibiotic treatment regimens for chronic periodontitis patients.  
 
 










Over the last 35 years, the issue of systemic antibiotics in periodontal therapy has evolved 
from initial research and controversy (1,2) to a scientific consensus recognizing their 
beneficial impact in the treatment of both aggressive and chronic forms of human 
periodontitis (3-9). 
 
However, many aspects related to the selection and administration of systemic periodontal 
antibiotic therapy remain unresolved (4). At present, most systemic periodontal antibiotic 
treatment regimens appear to be empirically prescribed by clinicians without guidance from 
a microbiological analysis of subgingival bacterial biofilm populations (10), even though 
patients with periodontitis frequently yield multiple species of periodontal pathogens that 
potentially vary in their antibiotic drug resistance (5). One of the risks of this approach is 
that an antibiotic drug may be selected to which the targeted periodontal pathogens are 
intrinsically resistant or poorly susceptible, compromising the efficacy of the antimicrobial 
therapy, and increasing the likelihood of a clinical treatment failure. A position paper for 
the American Academy of Periodontology (5) expressed concern about this potential 
adverse outcome, and advocated evaluation of antimicrobial susceptibility patterns of 
suspected periodontal pathogens prior to administration of systemic periodontal antibiotic 
therapy. In contrast, a European workshop on antimicrobial agents in periodontics 
concluded that “since the antimicrobial profiles of most putative periodontal pathogens are 
quite predictable, antimicrobial susceptibility testing seems to have no benefit” (11).   
 
Relative to this, recent data documents antibiotic resistance to be rare among fresh 
subgingival clinical isolates of periodontal pathogens tested from periodontitis patients 
residing in northern European countries, where antibiotic usage is generally restricted and 
infrequent (12). However, markedly higher levels of periodontal pathogen antibiotic 
resistance has been reported in other geographic regions of the world, such as in Spain in 
southern Europe and Columbia in South America, where there is less controlled antibiotic 
access and greater non-supervised consumption of these drugs than in northern Europe 
(13,14).      
 
In the United States, relatively little recent data exists on the extent to which antibiotic 
resistance occurs among subgingival periodontal pathogens in patients with periodontitis 
(15). As a result, it is not clear whether patients with periodontitis in the United States 
harbor subgingival periodontal pathogens with predictable antimicrobial susceptibility 
profiles, or instead, present with a more variable occurrence of sensitivity and resistance to 
antibiotics. To address this issue, the purpose of this study was to examine the occurrence 
of in vitro antibiotic resistance of selected periodontal pathogens in patients with chronic 
periodontitis in the United States to therapeutic antibiotic breakpoint concentrations of 
clindamycin, doxycycline, amoxicillin, and metronidazole, as well as to both amoxicillin 














A total of 400 adults (193 males, 207 females; aged 35-78 years; mean 50.5 r 9.9 (SD) 
years), diagnosed with severe chronic periodontitis (16) by periodontists in private dental 
practices in the United States, were included in the present study.  Their subgingival plaque 
samples were consecutively received and processed for microbiological analysis by the 
Oral Microbiology Testing Service (OMTS) Laboratory at Temple University School of 
Dentistry, Philadelphia. More than one-half of the study patients originated from dental 
practices located in the mid-Atlantic region of the United States (Maryland, Pennsylvania, 
New Jersey, Delaware, New York, Virginia, West Virginia and the District of Columbia), 
with the rest from 11 other eastern states and six midwest and western states. Samples from 
patients identified with aggressive periodontitis, or antibiotic use six months prior to 
sampling, were excluded. Approval for the study was provided by the Temple University 
Human Subjects Protections Institutional Review Board.  
 
Microbial sampling and transport 
 
Subgingival plaque specimens were obtained by the diagnosing periodontists, following a 
standardized sampling protocol, before treatment from three to five deep (> 6 mm) 
periodontal pockets per patient that exhibited bleeding on probing. After isolation with 
cotton rolls, and removal of saliva and supragingival plaque, one to two sterile, absorbent 
paper points (Johnson & Johnson, East Windsor, NJ, USA) were advanced into each 
selected periodontal site for approximately 10 seconds. Upon removal, all paper points per 
study patient were pooled in a glass vial containing six to eight small glass beads and 2.0 
ml of anaerobically prepared and stored VMGA III transport medium (17), which possesses 
a high preservation capability for oral microorganisms during post-sampling transit to the 
laboratory (17,18). The subgingival samples were then transported within 24 hours to the 
OMTS Laboratory, which is licensed for high-complexity bacteriological analysis by the 
Pennsylvania Department of Health. The OMTS Laboratory is also federally-certified by 
the United States Department of Health and Human Services to be in compliance with 
Clinical Laboratory Improvement Amendments-mandated proficiency testing, quality 
control, patient test management, personnel requirements, and quality assurance standards 
required of clinical laboratories engaged in diagnostic testing of human specimens in the 
United States (19). All laboratory procedures were performed by personnel who were 
blinded to the clinical status of the study subjects, and their inclusion in the present 
analysis.  
 
Microbial culture and incubation 
 
At the OMTS Laboratory, the specimen vials were warmed to 35ºC to liquefy the VMGA 
III transport medium, and sampled microorganisms were mechanically dispersed from the 
paper points with a Vortex mixer, which was used at the maximal setting for 45 seconds.  
Serial, 10-fold dilutions of the bacterial suspensions were prepared in Möller’s VMG I 
anaerobic dispersion solution, comprised of pre-reduced, anaerobically sterilized, 0.25% 
tryptose, 0.25% thiotone E peptone, and 0.5% NaCl (17). Then, 0.1 ml dilution aliquots 
were spread, with a sterile bent glass rod, onto non-selective enriched Brucella blood agar 
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(EBBA) primary isolation plates (20), comprised of 4.3% Brucella agar supplemented with 
0.3% bacto-agar, 5% defibrinated sheep blood, 0.2% hemolyzed sheep red blood cells, 
0.0005% hemin, and 0.00005% menadione, and onto selective trypticase soy-bacitracin-
vancomycin (TSBV) agar (21). EBBA plates were incubated at 35ºC for seven days in a 
Coy anaerobic chamber (Coy Laboratory Products, Ann Arbor, MI, USA) containing 85% 
N2, 10% H2, and 5% CO2, and TSBV plates were incubated at 35ºC for three days in air + 




Putative periodontal pathogens examined for in this study were Aggregatibacter actinomy-
cetemcomitans, Porphyromonas gingivalis, Prevotella intermedia/nigrescens, Parvimonas 
micra, Fusobacterium nucleatum, Streptococcus constellatus, Staphylococcus aureus, 
Enterococcus faecalis, gram-negative enteric rods/pseudomonads, and Candida species. 
 
Total anaerobic viable counts, and counts of P. gingivalis, P. intermedia/nigrescens, P. 
micra, F. nucleatum, S. constellatus, S. aureus and E. faecalis were made on EBBA 
primary isolation plates using a ring-light magnifying loupe, presumptive phenotypic 
methods previously described (15,22,23), and an enzyme-based, micro-method kit system 
(RapID ANA II, Innovative Diagnostic Systems, Atlanta, GA, USA) for selected isolates.  
A. actinomycetemcomitans, gram-negative enteric rods/pseudomonads, and Candida 
species were quantitated on TSBV agar, as previously described (20,21). The proportional 
recovery of each test species was ascertained in each patient by calculating as the 
percentage of test species colony-forming units relative to total subgingival anaerobic 
viable counts, as determined on non-selective EBBA primary isolation plates.  
 
In vitro antibiotic resistance testing 
 
Additional 0.1 ml aliquots of subgingival sample dilutions were inoculated onto EBBA 
primary isolation plates supplemented with either amoxicillin at 8 mg/L, clindamycin at 4 
mg/L, doxycycline at 4 mg/L, or metronidazole at 16 mg/L (all antimicrobials obtained as 
pure powder from Sigma-Aldrich, St. Louis, MO, USA), and incubated anaerobically for 
seven days. These antimicrobial concentrations represent non-susceptible/resistant break-
point concentrations against anaerobic bacteria for amoxicillin, clindamycin, and 
metronidazole as recommended by the Clinical and Laboratory Standards Institute (CLSI) 
(24), and for doxycycline as recommended by the French Society for Microbiology (25).  
Direct colony suspensions (equivalent to a 0.5 McFarland standard) of pure A. 
actinomycetemcomitans isolates from selective TSBV plates were subcultured onto these 
media as their recognition is frequently obscured within mixed bacterial populations (21).  
In vitro resistance to the antibiotic breakpoint concentrations was recorded when test 
species growth was noted on the respective antibiotic-supplemented EBBA plates 
(15,20,26,27). Bacteroides thetaiotaomicron ATCC 29741, Clostridium perfringens ATCC 
13124, and a multi-antibiotic-resistant clinical periodontal isolate of F. nucleatum were 
used as positive and negative quality controls for all antibiotic resistance testing on drug-
supplemented EBBA plates.   
 
Gram-negative enteric rods/pseudomonads recovered on TSBV primary isolation plates 




the organisms, equivalent to a 0.5 McFarland standard, were inoculated onto Mueller-
Hinton agar, incubated in ambient air at 35qC for 16 to 18 hours, and assessed with CLSI 




The recovered test periodontal pathogens were grouped for reporting purposes into 
subgingival bacterial clusters (i.e., red complex, orange complex, and other species), as 
previously described (29). Descriptive analysis was used to tabulate the occurrence and 
proportional cultivable recovery of test species in patients, as well as the occurrence and 
subgingival proportions of antibiotic-resistant test species. Based on previous studies 
demonstrating excellent agreement (98.5%) between periodontal pathogen antibiotic 
resistance patterns on EBBA plates jointly supplemented with both amoxicillin and 
metronidazole, and those determined from a post-hoc combination of findings from EBBA 
plates individually supplemented with amoxicillin or metronidazole (30), the in vitro 
antibiotic resistance data for the 400 study patients was combined and analyzed post-hoc 
for amoxicillin and metronidazole-supplemented EBBA primary isolation plates. Data 
analysis was performed using a statistical software package (SAS 9.2 for Windows, SAS 




Total cultivable counts and test species recovery 
 
Total subgingival anaerobic viable counts on non-antibiotic-supplemented EBBA primary 
isolation plates averaged 4.0 x 107 ± 2.4 x 106 (SE) organisms/ml of sample (range = 9.0 x 
105 to 4.2 x 108 organisms/ml). 
 
Table 1 lists the occurrence and proportional cultivable recovery of subgingival test species 
recovered from the 400 study patients. P. micra, P. intermedia/nigrescens and P. gingivalis 
were isolated from most study patients (78% to 91%), with mean subgingival proportions 
of these species in positive patients ranging from 10.3% to 18.1% of cultivable anaerobic 
viable counts. A. actinomycetemcomitans, S. constellatus, and F. nucleatum were detected 
in 20.3% to 36.8% of the study patients. Gram-negative enteric rods/pseudomonads 
averaged 24.6% of the cultivable subgingival microbiota in nine (2.3%) positive patients, of 
which six had gram-negative enteric rods/pseudomonads >10% of total subgingival counts. 
E. faecalis and S. aureus were detected in four (1.0%) and one (0.3%) of the study patients, 
respectively. No subgingival Candida species were isolated in the study population with the 
employed microbiological methods.      
 
In vitro antibiotic resistance testing  
 
Table 2 lists the occurrence of in vitro antibiotic resistance among the test periodontal 
pathogens in the 400 study patients. P. gingivalis rarely showed in vitro resistance to any of 
the test antibiotics. In comparison, 76 of 81 (93.8%) patient strains of A. actinomycetem-
comitans exhibited in vitro resistance to clindamycin at 4 mg/L, and 38 of 81 (46.9%) 
strains to doxycycline at 4 mg/L, whereas relatively few were resistant in vitro to either 
amoxicillin or metronidazole (3.7% to 6.1% of patient strains). Subgingival proportions of 
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antibiotic-resistant A. actinomycetemcomitans clinical isolates averaged from 2.1% to 
22.7% of the subgingival cultivable microbiota.   
 
P. intermedia/nigrescens was rarely resistant in vitro to metronidazole, and infrequently to 
clindamycin. However, 89 of the 320 (27.8%) P. intermedia/nigrescens patient strains were 
resistant to doxycycline, and 108 (33.8%) resistant to amoxicillin, with antibiotic-resistant 
strains averaging 13.7% of cultivable subgingival viable counts. Both P. micra and F. 
nucleatum displayed in vitro resistance to doxycycline in 67 and 11 persons, respectively, 
and less frequently to other test antibiotics. S. constellatus in most species-positive indivi-
duals (89.1%) was resistant in vitro to metronidazole. A total of 52 (35.4%) S. constellatus 
patient strains were resistant to amoxicillin, 35 (23.8%) resistant to doxycycline, and nine 
(6.1%) resistant to clindamycin. Antibiotic-resistant S. constellatus strains averaged 5% to 
6% of cultivable subgingival organisms in culture-positive persons (Table 2).   
 
All isolated subgingival gram-negative enteric rods/pseudomonads in nine positive patients 
were resistant in vitro to each of the four test antibiotics, but were susceptible to 
ciprofloxacin in disk diffusion testing. Each of these individuals was co-colonized by one 
or more metronidazole-susceptible periodontal pathogens, including P. gingivalis, P. 
intermedia/nigrescens, and P. micra, and one patient additionally had metronidazole-
resistant S. constellatus.   
 
Subgingival S. aureus in the one positive person was resistant in vitro to each of the four 
test antibiotics. Subgingival E. faecalis was resistant to metronidazole and doxycycline in 
all four positive patients, to clindamycin in three patients, and to amoxicillin in two patients 
(Table 2). 
 
When data for in vitro resistance to amoxicillin at 8 mg/L and metronidazole at 16 mg/L 
were combined and analyzed post hoc (Table 2), resistance to both antibiotic concentra-
tions occurred with 45 patient strains of S. constellatus, nine of gram-negative enteric rods/ 
pseudomonads, two of E. faecalis, and one each of S. aureus¸ P. intermedia/nigrescens, and 
A. actinomycetemcomitans. 
 
Overall, antibiotic-resistant subgingival periodontal pathogens were detected in 297 
(74.2%) of the 400 study patients. One or more test periodontal pathogens resistant in vitro 
to doxycycline were found in 220 (55.0%) patients, to amoxicillin in 173 (43.3%) patients, 
to metronidazole in 121 (30.3%) patients, and to clindamycin in 106 (26.5%) patients. In 
addition, 60 (15.0%) of the study patients harbored subgingival test periodontal pathogens 




























































   
   
   
   
   





















































































































































































































































































































































































































































   
   
   
   



























































































































































































































































































































































































































































































































































































































































































































































































































This in vitro study assessed subgingival periodontal pathogen antibiotic resistance in the 
largest number of periodontitis patients in the United States (n = 400) since the report of 
Listgarten et al. (31) 20 years ago on 196 refractory periodontitis patients. The major 
finding was the frequent occurrence of antibiotic resistance among subgingival periodontal 
pathogens colonizing chronic periodontitis patients in the United States, which appears to 
be greater than is found in chronic periodontitis patients in northern Europe (12,13,27). No 
single evaluated antibiotic, or combination of antibiotics, demonstrated in vitro inhibition 
of all of the assessed periodontal pathogens across all of the study patients.      
 
Resistance to doxycycline in the study patients was most striking, with 55% revealing one 
or more of the test periodontal pathogens resistant to doxycycline at a breakpoint 
concentration of 4 mg/L. P. micra, P. intermedia/nigrescens, and A. actinomycetem-
comitans most frequently displayed doxycycline resistance among 18.4% to 46.9% of 
recovered patient strains. These frequencies of doxycycline resistance are relatively similar 
to tetracycline-HCl resistance detected in P. micra and P. intermedia/nigrescens subging-
ival strains in Germany (32), but markedly higher than reported for periodontal A. 
actinomycetemcomitans clinical isolates in France (33). Moreover, the doxycycline 
resistance detected in present-day periodontal A. actinomycetemcomitans clinical isolates in 
the United States (Table 2) appears to be considerably greater compared to the rare A. 
actinomycetemcomitans resistance to tetracycline family antibiotics that was reported more 
than 30 years ago (34). Consistent with these in vitro findings, no statistically significant 
reductions in doxycycline-resistant subgingival strains of P. micra and P. intermedia/ 
nigrescens were found in vivo following systemic doxycycline administration in patients 
with periodontitis (35).    
 
Amoxicillin resistance was present in 43.3% of the study patients, primarily among 
subgingival P. intermedia/nigrescensZKLFKRIWHQHODERUDWHVȕ-lactamase enzymes capable 
RI K\GURO\]LQJ ȕ-lactam antibiotics such as amoxicillin (36). About one-third of 147 
subgingival S. constellatus patient strains were resistant to amoxicillin, which is higher than 
reported in another recent S. constellatus study by our group involving a smaller number of 
clinical isolates (unpublished observations). Large transient increases in amoxicillin-
resistant subgingival S. constellatus have been detected following systemic amoxicillin 
therapy in patients with chronic periodontitis (35). 
 
Resistance to metronidazole occurred in subgingival biofilm specimens from 30.3% of the 
study patients, and as expected, was found almost exclusively among non-anaerobic test 
species, including S. constellatus, gram-negative enteric rods/pseudomonads, E. faecalis, 
and S. aureus. Metronidazole resistance among anaerobic periodontal pathogens was rarely 
noted in this study (Table 2), similar to anaerobic periodontal isolates in Europe (12,13,27), 
but in contrast to the approximately 20% to 25% metronidazole resistance rate reported in 
Columbia for subgingival P. gingivalis, P. intermedia/nigrescens, and F. nucleatum clinical 
isolates (14). Clinical studies have found no statistically significant reductions in 
metronidazole-resistant subgingival strains of S. constellatus after systemic metronidazole 
administration in patients with periodontitis (35).     
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About one-fourth of the study patients had periodontal pathogens resistant to clindamycin, 
most frequently among A. actinomycetemcomitans clinical isolates, consistent with other 
studies performed elsewhere in the world (12-14,33). Clindamycin resistance is absent or 
infrequent in anaerobic periodontal pathogens (Table 2) (12), consistent with clinical 
studies documenting suppression of a similar array of anaerobic periodontal pathogens, 
leading to marked clinical improvements, after systemic clindamycin therapy in patients 
with refractory periodontitis (37).  
 
A total of 60 (15%) of the study patients harbored subgingival test periodontal pathogens 
resistant to both amoxicillin at 8 mg/L and metronidazole at 16 mg/L, which was the lowest 
level of patient resistance detected among the evaluated antibiotics. This confirms 
suggestions that the complementary antimicrobial spectrums of amoxicillin and 
metronidazole inhibit a wider array of periodontal pathogens than individual antibiotics, 
and pose a lower risk of encountering drug-resistant pathogenic species (5). Species 
resistant to both antibiotic concentrations included S. constellatus (30.6% of patient 
strains), all gram-negative enteric rods/pseudomonads and S. aureus clinical isolates, two of 
four E. faecalis subject strains, and one patient strain each of A. actinomycetemcomitans 
and P. intermedia/nigrescens. Despite a number of clinical studies finding marked 
improvements in patients with periodontitis prescribed systemic amoxicillin plus 
metronidazole (6-9), not all periodontitis patients treated with this drug combination appear 
to clinically respond in an equivalent fashion. A subset of periodontitis patient outcomes 
from systemic amoxicillin plus metronidazole therapy appear to be no better than placebo 
control groups (38-40), particularly in the absence of subgingival P. gingivalis (38). It is 
tempting to speculate that another potential determinant for this differential clinical effect 
of systemic amoxicillin plus metronidazole antibiotic therapy may be the presence of 
periodontal pathogens resistant to therapeutic concentrations of both drugs, similar to those 
detected in this study.       
 
In this regard, nine study patients yielded subgingival gram-negative enteric rods/ 
pseudomonads resistant to both amoxicillin and metronidazole, which suggests that 
potential administration of these two antibiotics as a part of periodontal therapy may be 
ineffective against these species, potentially compromising clinical outcomes (20,41).  
Doxycycline and clindamycin also appear unlikely to be viable alternatives in light of their 
negligible antimicrobial activity against gram-negative enteric rods/pseudomonads (Table 
2). A combination of ciprofloxacin plus metronidazole (5) may be more appropriately 
considered for the six study patients with ciprofloxacin-sensitive gram-negative enteric 
rods/pseudomonads greater than 10% of the cultivable subgingival microbiota, and 
additionally harboring metronidazole-susceptible co-colonizing periodontal pathogens, 
because mechanical periodontal debridement does not reliably suppress large subgingival 
populations of gram-negative enteric rods/pseudomonads (41). In contrast, the three study 
patients with lower proportions of subgingival gram-negative enteric rods/pseudomonads 
may have adequate suppression of these species via conventional periodontal debridement 
procedures without a need for systemic antibiotic therapy (41). 
 
The present in vitro study data has several limitations. The actual systemic periodontal 
antibiotic treatment needs, if any, of the study patients with chronic periodontitis were not 
determined. The study patients represent a private dental practice-based convenience 




United States. Because no clinical or radiographic evaluations of the study subjects were 
conducted by calibrated examiners, independent of the private practice periodontists who 
submitted the subgingival biofilm specimens for microbiological testing, doubt may be 
raised about their diagnosis of chronic periodontitis in the study patients. However, their 
identification of three or more periodontal sites with deep probing depths and bleeding on 
probing in the study patients strongly correlates (94.1% positive predictive value) with a 
finding of severe periodontal attachment loss in adult patients (42). Only selected 
periodontal pathogens were evaluated in the subgingival biofilm specimens studied, 
without inclusion of additional cultivable periodontal bacterial species and Archaea 
implicated in the pathogenesis of periodontitis (43), which may possess even more diverse 
antibiotic susceptibility profiles. The occurrence and counts of F. nucleatum were likely 
underestimated on EBBA primary culture plates examined without a stereomicroscope in 
addition to a ring-light magnifying loupe (15). Exact minimal inhibitory concentration 
values of the test antibiotics against the detected periodontal pathogens were not 
determined with the clinical laboratory methods followed, and antibiotic resistance genes in 
the test periodontal pathogens were not studied. Moreover, the extent to which our in vitro 
laboratory findings may assist periodontal therapy in vivo and enhance clinical treatment 
outcomes remains to be fully established and validated.  
   
In addition, the present study design differs from traditional investigations of bacterial 
antibiotic susceptibility, where evaluated species are tested individually after subculture, 
and minimal inhibitory concentrations reported without regard to the antimicrobial profile 
of other periodontal pathogens colonizing homologous persons (12-14). Instead, in vitro 
antibiotic resistance testing was performed on primary isolation plates, and tabulated across 
all test periodontal pathogens positive within each study patient (15), which more closely 
parallels what clinicians routinely confront in practice in determining potential periodontal 
antibiotic therapy needs of individual periodontitis patients. This direct plating method has 
been employed in previous periodontal microbiology studies (15,20,26,27,31,36), and 
correlates well (r2 = 0.99) with the CLSI-approved agar dilution susceptibility assay in 
identifying antibiotic-resistant periodontal microorganisms (26). Similarly, a 94% agree-
ment rate has been reported between primary (direct) versus secondary (subculture) 
antibiotic susceptibility plate testing on acute dentoalveolar abscess bacterial isolates (44).   
  
It is important to emphasize that in vitro identification of antibiotic sensitivity in 
subgingival periodontal pathogens does not necessarily confer in vivo drug effectiveness 
against the organisms (45), since additional factors may impact passage of antibiotics into 
periodontal pockets, and alter their activity against mixed infections growing in biofilms 
(5). As a result, this study focused on periodontal pathogen antibiotic resistance, because it 
is recognized that patients presenting with drug-resistant pathogens generally demonstrate a 
poorer bacteriological response to antimicrobial therapy than patients infected with drug-
susceptible organisms (46). However, documentation of antibiotic-resistant periodontal 
pathogens causing clinical periodontal treatment failure is limited in the periodontology 
scientific literature, and likely underrepresents its occurrence in clinical periodontal 
practice. Examples of such patient outcomes were described nearly 20 years ago by Fine 
(47). Tetracycline-resistant strains of subgingival Aggregatibacter actinomycetemcomitans 
were associated in one patient with progressive periodontitis occurring after long-term 
systemic tetracycline-HCl therapy and multiple periodontal flap surgeries (47). Another 
patient revealed high subgingival levels of erythromycin-resistant Staphylococcus aureus in 
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highly disease-active periodontitis lesions secondary to prolonged systemic erythromycin 
therapy and multiple periodontal surgeries (47). In both of these patients, alternative 
systemic antibiotic therapy, selected on the basis of microbiological analysis and in vitro 
antibiotic susceptibility testing, led to suppression of the pathogenic species and a sustained 
clinical resolution. Similarly, Colombo et al. (48) reported that elevated baseline 
proportions of subgingival S. constellatus, which is frequently resistant to tetracycline 
antibiotics (Table 2), and poorly removed by periodontal root instrumentation (49), 
conferred an 8.6 odds ratio for post-treatment progressive periodontal attachment loss on 
refractory chronic periodontitis patients treated with surgical debridement and a 28-day 
systemic tetracycline drug regimen. It is likely that antibiotic susceptibility testing in 
clinical situations like these may be clinically directive to dental professionals in their 
selection of periodontal antimicrobial therapies, and help reduce the risk of treatment 





Chronic periodontitis subjects in this study frequently yielded subgingival periodontal 
pathogens resistant in vitro to therapeutic concentrations of antibiotics commonly utilized 
in clinical periodontal practice. The wide variability in periodontal pathogen antibiotic 
resistance patterns should concern clinicians empirically selecting antibiotic treatment 
regimens for chronic periodontitis patients, and suggests a role for microbiological analysis 
and antibiotic susceptibility testing as an aid in the selection of systemic periodontal 
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Purpose: The occurrence of in vitro resistance to therapeutic concentrations of spiramycin, 
amoxicillin, and metronidazole was determined for putative periodontal pathogens isolated 
in the United States. 
 
Materials and methods: Subgingival plaque specimens from 37 consecutive adults with 
untreated severe periodontitis were anaerobically cultured, and isolated putative periodontal 
pathogens were identified to a species level. In vitro resistance to spiramycin at 4 mg/L, 
amoxicillin at 8 mg/L, and/or metronidazole at 16 mg/L was noted when putative 
periodontal pathogen growth was noted on the respective antibiotic-supplemented primary 
culture plates.   
 
Results: A total of 18 (48.7%) subjects yielded antibiotic-resistant putative periodontal 
pathogens with spiramycin at 4 mg/L in drug-supplemented primary isolation plates, as 
compared to 23 (62.2%) subjects with amoxicillin at 8 mg/L, and 10 (27.0%) subjects with 
metronidazole at 16 mg/L. Spiramycin in vitro resistance occurred among species of 
Fusobacterium nucleatum (44.4% of organism-positive subjects), Prevotella intermedia/ 
nigrescens (11.1%), Parvimonas micra (10.8%), Streptococcus constellatus (10%), 
Streptococcus intermedius (10%), Porphyromonas gingivalis (6.7%), and Tannerella 
forsythia (5.3%). Amoxicillin in vitro resistance was found in P. intermedia/nigrescens 
(55.5%), T. forsythia (15.8%), S. constellatus (10%), F. nucleatum (5.6%), and P. micra 
(2.7%). Only S. constellatus (70%) and S. intermedius (40%) exhibited in vitro resistance to 
metronidazole. When subject-based resistance data for spiramycin and metronidazole were 
jointly considered, all isolated putative periodontal pathogens were inhibited in vitro by one 
or the other of the antibiotic concentrations, except for one strain each of S. constellatus 
and S. intermedius from one study subject. Similarly, either amoxicillin or metronidazole at 
the drug concentrations tested inhibited in vitro all recovered putative periodontal 
pathogens, except S. constellatus in one subject.   
 
Conclusions: In vitro spiramycin resistance among putative periodontal pathogens of 
United States origin occurred in approximately one-half of severe periodontitis patients 
evaluated, particularly among subgingival F. nucleatum species. In vitro resistance patterns 
also suggest that therapeutic concentrations of spiramycin plus metronidazole may have 
potential antimicrobial efficacy in non-Aggregatibacter actinomycetemcomitans-associated 
periodontitis similar to amoxicillin plus metronidazole, which may be beneficial, where 









Spiramycin is a medium-spectrum, 16-membered, macrolide antibiotic widely used in the 
treatment of respiratory infections (1), except in the United States, where it is available by 
special permission for treatment of toxoplasmosis in women during the first trimester of 
pregnancy. Since the drug enters the oral cavity through gingival crevicular fluid and 
saliva, and persists for extended periods at potentially therapeutic concentrations (2), 
spiramycin is also prescribed in some countries for various odontogenic infections, 
including endodontic abscesses, pericoronitis, and destructive forms of periodontal disease 
(periodontitis) (3-6). 
 
A number of studies have assessed the antimicrobial activity of spiramycin on putative 
periodontopathic bacteria in subgingival plaque biofilms (7-17). Except for ones completed 
over 25 years ago (7-9), these studies focused on clinical isolates from periodontitis patients 
located outside of the United States. Since geographic differences (18), and emergence of 
drug-resistant strains over time (19), may markedly alter antibiotic susceptibility patterns of 
subgingival bacterial species, the present-day antimicrobial effects of spiramycin on 
putative periodontal pathogens in the United States remain speculative.   
 
The present study examined, using fresh subgingival isolates from periodontitis patients in 
the United States, the occurrence of in vitro resistance among putative periodontal 
pathogens to therapeutic concentrations of spiramycin, as well as amoxicillin and 
metronidazole. 
 




A total of 37 adults (17 males, 20 females; aged 35-85 years; mean 57.5 r 12.0 (SD) years), 
diagnosed with severe periodontitis (20) by periodontists in United States private dental 
practices, were consecutively included in the present study as their microbiological samples 
were received by the testing laboratory. Persons identified with aggressive periodontitis, or 
antibiotic use within the past six months, were excluded. Only four (10.8%) of the study 
subjects were reported as current smokers.   
 
Microbial sampling and transport 
 
Subgingival plaque specimens were obtained by each study subject’s periodontist, 
following a standardized sampling protocol, prior to treatment from the three to five 
deepest periodontal pockets (mean 7.5 ± 0.3 (SE) mm) per subject which exhibited 
bleeding on probing. In brief, after isolation with cotton rolls, and removal of saliva and 
supragingival deposits, one to two sterile, absorbent paper points (Johnson & Johnson, East 
Windsor, NJ, USA) were advanced into each selected periodontal site for approximately 10 
seconds. Upon removal, all paper points per study subject were pooled into a glass vial 
containing six to eight small glass beads and 2.0 ml of anaerobically prepared and stored 
VMGA III transport medium (21), which possesses a high preservation capability for oral 
microorganisms during post-sampling transit to the laboratory (21,22). The subgingival 
samples were then transported within 24 hours to the Oral Microbiology Testing Service 
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(OMTS) Laboratory at Temple University School of Dentistry, which is licensed for high 
complexity bacteriological analysis by the Pennsylvania Department of Health.  
 
Microbial culture and incubation 
 
At the OMTS Laboratory, the specimen vials were warmed to 35ºC to liquefy the VMGA 
III transport medium, and sampled microorganisms were mechanically dispersed from the 
paper points with a vortex mixer at the maximal setting for 45 seconds. Serial 10-fold 
dilutions of dispersed bacteria were prepared in Möller’s VMG I anaerobic dispersion 
solution (21). Appropriate dilution aliquots were plated onto non-selective enriched 
Brucella blood agar (EBBA) (23), Hammond’s selective Campylobacter medium (24), and 
TSBV agar (25). Aliquots were also plated onto EBBA supplemented with either 
spiramycin at 4 mg/L, amoxicillin at 8 mg/L, or metronidazole at 16 mg/L (all 
antimicrobials were obtained as pure powder from Sigma-Aldrich, St. Louis, MO, USA).  
These antimicrobial concentrations represent non-susceptible/resistant breakpoint concen-
trations for anaerobic bacteria recommended by the French Society for Microbiology (26) 
for spiramycin, and the Clinical and Laboratory Standards Institute (CLSI) (27) for 
amoxicillin and metronidazole. All EBBA and Hammond’s selective medium plates were 
incubated at 35ºC for seven days in a Coy anaerobic chamber (Coy Laboratory Products, 
Ann Arbor, MI, USA) containing 85% N2-10% H2-5% CO2, and TSBV plates were 




On non-selective EBBA plates examined with a ring-light magnifying loupe and a 
dissecting stereomicroscope, the presence and levels of total anaerobic viable counts, 
Porphyromonas gingivalis, Prevotella intermedia/nigrescens, Parvimonas micra, staphy-
lococci and enterococci were determined using presumptive phenotypic methods previously 
described (28-31); Tannerella forsythia was identified as gram-negative, non-motile, 
anaerobic rods exhibiting grey-pink speckled, convex, pinpoint colonies seen with a 
stereomicroscope, lack of long-wave ultraviolet light autofluorescence, and a positive 
CAAM test for trypsin-like activity (28); Fusobacterium nucleatum was identified as long-
wave ultraviolet light autofluorescent charteuse-positive (32), gray, iridescent colonies of 
gram-negative, filamentous, spindle-shaped, non-motile rods; Streptococcus intermedius 
was recognized as gram-positive, lactose MUG-test positive (33), non-motile, facultative 
cocci exhibiting small dry, white, raised colonies with wrinkled edges; and Streptococcus 
constellatus was defined as gram-positive, lactose MUG-test negative, non-motile, 
facultative cocci demonstrating small white, opaque, circular, beta-hemolytic, surface 
FRORQLHV ZLWK LUUHJXODU HGJHV DQG SRVLWLYH IRU Į-D-glucosidase enzyme activity, with or 
ZLWKRXWȕ-D-IXFRVLGDVHRUȕ-D-glucosidase positive reactions, as determined with the Fluo-
Card Milleri test kit (Key Scientific Products Co., Stamford, TX, USA) (34).  
Campylobacter rectus was quantitated on Hammond’s medium, and Aggregatibacter 
actinomycetemcomitans, gram-negative enteric rods, pseudomonads, and Candida species 
on TSBV agar, as previously described (23,25,35). Proportional subject recovery of the 
various test putative periodontal pathogens was calculated as the percent recovery of the 
test species colony forming units (CFU) among the total subgingival anaerobic viable CFU 





In vitro antibiotic resistance testing 
 
In vitro resistance to the antibiotic breakpoint concentrations of spiramycin (4 mg/L), 
amoxicillin (8 mg/L), or metronidazole (16 mg/L) was recorded per subject when test 
putative periodontal pathogen growth was noted on antibiotic-supplemented and non-
supplemented primary isolation EBBA plates (23,36,37). Bacteroides thetaiotaomicron 
ATCC 29741, Clostridium perfringens ATCC 13124, and a multi-antibiotic-resistant 
clinical periodontal isolate of F. nucleatum were employed as positive and negative quality 




Recovered test putative periodontal pathogens were grouped for reporting purposes into 
subgingival bacterial clusters (i.e., red complex, orange complex, and other species) 
described by Socransky et al. (38). Descriptive analysis was used to calculate the subject 
occurrence and proportional cultivable recovery of test putative periodontal pathogens on 
non-selective EBBA, and the subject occurrence of in vitro test putative periodontal 
pathogen antibiotic resistance. In vitro data was also combined post-hoc for spiramycin and 
metronidazole, and for amoxicillin and metronidazole, to determine the number and 
proportion of organism-positive study subjects where test putative periodontal pathogens 
exhibited in vitro resistance to both antibiotics at the employed non-susceptible breakpoint 
concentrations. 
 
Study parameters and approval 
 
All microbiological procedures were performed on a standardized, blinded basis without 
knowledge of the clinical status of the study subjects, or their inclusion in the present 
analysis. Approval for the study was provided by the Temple University Human Subjects 




Total cultivable counts and putative periodontal pathogen recovery 
 
Total subgingival anaerobic viable counts on non-antibiotic-supplemented EBBA plates 
averaged 7.32 x 107 ± 1.6 x 107 (SE) organisms/ml of sample in the study subjects (range = 
2 x 106 to 3.5 x 108 organisms/ml). 
 
Table 1 lists the distribution of recovered subgingival test putative periodontal pathogens in 
the 37 study subjects. Among red complex bacterial species, P. gingivalis was isolated from 
15 (40.5%) subjects, and T. forsythia from 19 (51.4%) subjects, at mean subgingival 
proportions of 14.4% and 1.4%, respectively, in culture-positive subjects. Among orange 
complex and other species, P. micra was isolated from all 37 subjects, P. intermedia/ 
nigrescens and F. nucleatum were each found in 36 (97.3%) subjects, C. rectus was 
recovered from 20 (54.1%) subjects, and S. constellatus and S. intermedius were each 
present in 10 (27.0%) subjects (Table 1). Cultivable subgingival A. actinomycetemcomi-
tans, gram-negative enteric rods, pseudomonads, staphylococci, enterococci and Candida 
species were not detected in any of the study subjects. 
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In vitro antibiotic resistance testing  
 
A total of 18 (48.7%) subjects yielded antibiotic-resistant putative periodontal pathogens 
with spiramycin at 4 mg/L in drug-supplemented primary isolation plates, as compared to 
23 (62.2%) subjects with amoxicillin at 8 mg/L, and 10 (27.0%) subjects with metronida-
zole at 16 mg/L.     
 
F. nucleatum most frequently exhibited in vitro spiramycin resistance, with 44.4% of 
subject strains resistant to 4 mg/L of spiramycin in primary isolation plates (Table 2).  
Between 10-11% of subject strains each of P. intermedia/nigrescens, P. micra, and S. 
intermedius demonstrated in vitro spiramycin resistance, and one subject strain each of P. 
gingivalis and T. forsythia were resistant in vitro to non-susceptible breakpoint concentra-
tions of spiramycin (Table 2). 
 
Amoxicillin at 8 mg/L in primary isolation plates inhibited all subject strains of P. 
gingivalis, C. rectus, and S. intermedius. In contrast, 55.5% of P. intermedia/nigrescens 
subject strains, and 2.7-15.8% of T. forsythia, S. constellatus, F. nucleatum, and P. micra 
subject strains displayed in vitro resistance to 8 mg/L of amoxicillin in primary isolation 
plates (Table 2).   
 
All subject strains of P. gingivalis, T. forsythia, P. intermedia/nigrescens, P. micra, C. 
rectus, and F. nucleatum were inhibited in vitro by 16 mg/L of metronidazole in primary 
isolation plates. However, 70% of S. constellatus, and 40% of S. intermedius subject 
strains, revealed in vitro resistance to 16 mg/L of metronidazole (Table 2). 
 
When subject-based in vitro resistance data for 4 mg/L of spiramycin and 16 mg/L of 
metronidazole were jointly considered post hoc, all isolated test periodontal pathogens were 
inhibited in vitro by one or the other of the antibiotic concentrations, except for one strain 
each of S. constellatus and S. intermedius in one (2.7%) study subject. Similarly, either 8 
mg/L of amoxicillin or 16 mg/L of metronidazole inhibited in vitro all recovered test 
















































































   
   
   
   






































































































































































































































































































































































































   
   
   
   























































































































































































































































































































































































































































































The present study findings represent the first data in over 25 years on in vitro spiramycin 
resistance in putative periodontal pathogens in the United States. In vitro resistance among 
recovered putative periodontal pathogens to spiramycin at 4 mg/L was found in 48.7% of 
severe periodontitis patients evaluated, which was less in vitro resistance than occurred 
with amoxicillin at 8 mg/L (62.2% of subjects), but more than was found with 
metronidazole at 16 mg/L (27.0%). These findings highlight the considerable subject 
variation seen across single antibiotic drugs in their antimicrobial effects against putative 
periodontal pathogens, which can markedly influence the selection and efficacy of 
periodontal antibiotic treatment regimens (39). 
 
Among individual microbial species, most red and orange complex organisms, which are 
associated with increasingly more severe forms of periodontitis (38), were inhibited in vitro 
by spiramycin at 4 mg/L in primary isolation plates (Table 2). However, F. nucleatum was 
frequently resistant in vitro to spiramycin (44.4% of subject strains), consistent with 
previous reports on periodontitis stains from the United States (8,9) and other countries 
(5,12,13,16,17,40). Some subject strains of P. gingivalis, T. forsythia, P. intermedia/ 
nigrescens and P. micra also exhibited in vitro resistance to spiramycin, but at lower 
proportions than homologous species strains previously isolated and tested in France (16).  
For reasons to be determined, all C. rectus in the present study were inhibited in vitro by 
spiramycin at 4 mg/L in primary isolation plates, as compared to 80% C. rectus resistance 
to spiramycin at the same in vitro concentration in France (17). 
 
Since there is negligible spiramycin use in the general United States population, it is 
unlikely that the spiramycin resistance detected in the present study subjects is the result of 
prior spiramycin drug exposures promoting selection of resistant microbial species, in 
contrast to persons in countries where spiramycin is extensively prescribed. Instead, the 
increasing dissemination among gram-negative bacteria, via mobile plasmids and/or 
conjugative transposons, of various drug resistance genes active against all macrolide-class 
antibiotics may account for in vitro spiramycin resistance among periodontal 
microorganisms not previously exposed to spiramycin (41,42). However, the molecular 
basis for the in vitro spiramycin drug resistance detected in the present study remains to be 
determined.  
 
In vitro resistance to amoxicillin included most P. intermedia/nigrescens subject strains, 
and a smaller subset of T. forsythia, S. constellatus, F. nucleatum, and P. micra, with 
metronidazole resistance found only among most S. constellatus and some S. intermedius 
clinical isolates, similar to previous reports (13,18,37,40).   
 
The direct plating method used in this study to detect antibiotic resistance on primary 
culture plates has been previously used in a number of periodontal microbiology studies 
(23,36,37), and shown to highly correlate (r2 = 0.99) with the CLSI-approved multiple agar 
dilution assay in successfully identifying antibiotic-resistant periodontal microorganisms 
(36). Similarly, Lewis et al. (43) reported a 94% agreement between primary versus 
secondary (subculture) antibiotic susceptibility plate testing of acute dentoalveolar abscess 
bacterial isolates. The relatively high viable anaerobic counts (on average in excess of 107 
organisms/ml) recovered on non-selective EBBA media in the present study suggests that 
Spiramycin resistance in periodontitis microbiota 
109 
 
an adequate subgingival sample inoculum was spread on antibiotic-supplemented primary 
isolation plates examined for resistant species growth. However, the inability to determine 
exact minimal inhibitory concentration (MIC) values of antimicrobials tested against 
microbial species is a shortcoming of this approach, since only non-susceptible/resistant 
breakpoint concentrations, as recommended by the French Society for Microbiology (26) 
for spiramycin, and the Clinical and Laboratory Standards Institute (27) for amoxicillin and 
metronidazole, were employed per antibiotic in the in vitro resistance testing. Nevertheless, 
identification of in vitro periodontal pathogen resistance to therapeutic concentrations of 
antimicrobials contemplated for patient care is highly relevant and clinically practical to 
dentists striving to avoid prescribing antibiotics ineffective against drug-resistant 
pathogens. 
 
Since increasing interest has developed on use of combination systemic antibiotic regimens 
in periodontitis treatment, where two antibiotics with complementary antibacterial activity 
are administered to broaden the spectrum of antimicrobial effects against subgingival and 
soft tissue-invading bacterial pathogens (39,44), the present study also jointly considered 
subject-based resistance data post hoc for spiramycin at 4 mg/L plus metronidazole at 16 
mg/L. Interestingly, all isolated putative periodontal pathogens were inhibited in vitro by 
one or the other of the antibiotic concentrations in primary isolation plates, except for one 
strain each of S. constellatus and S. intermedius from one (2.7%) study subject. Since the 
two antibiotic concentrations were not incorporated together into antibiotic-supplemented 
primary isolation plates, no conclusions can be drawn about synergistic drug effects of 
spiramycin plus metronidazole against oral bacterial species, which have been noted in 
some previous studies (5,10,11,40). However, these favorable microbiological effects are 
consistent with the results of a double-blind clinical trial finding systemic spiramycin plus 
metronidazole to significantly enhance gains of clinical periodontal attachment on initially 
deep periodontal pockets at six months post-treatment on adults with severe periodontitis 
(45). 
 
A similar post hoc joint analysis also found either amoxicillin at 8 mg/L or metronidazole 
at 16 mg/L in primary isolation plates inhibited all recovered putative periodontal 
pathogens, except S. constellatus in one (2.7%) subject, which is also consistent with 
clinical trials demonstrating enhanced therapeutic benefits of systemic amoxicillin plus 
metronidazole in aggressive and chronic periodontitis therapy (44). 
 
While the periodontists who performed clinical examinations in the present study were not 
formally calibrated, support for their severe periodontitis diagnoses was evidenced by their 
identification in the study subjects of three or more periodontal sites with deep probing 
depths with bleeding on probing (mean 7.5 mm at microbiologically-sampled periodontal 
sites), which strongly correlates (94.1% positive predictive value) with the presence of 
severe periodontal attachment loss in adult patients (46).    
 
Overall, these findings suggest that the in vitro effectiveness of spiramycin against putative 
periodontal pathogens can be enhanced by broadening its antimicrobial spectrum with 
metronidazole, and that the joint in vitro antimicrobial effects of spiramycin plus 
metronidazole against a wide range of putative periodontal pathogens appears to be similar 
to that seen with amoxicillin plus metronidazole. Thus, a clinical periodontitis treatment 




have potential therapeutic efficacy similar to the combination of amoxicillin plus metro-
nidazole, and may be particularly beneficial as an alternative for periodontitis patients 
hypersensitive to amoxicillin or other beta-lactam antibiotics, and not colonized by A. 




In vitro spiramycin resistance among putative periodontal pathogens of United States origin 
was found in approximately one-half of severe periodontitis patients evaluated, particularly 
among F. nucleatum species. In vitro resistance patterns also suggest that therapeutic 
concentrations of spiramycin plus metronidazole may have potential antimicrobial efficacy 
in non-A. actinomycetemcomitans-associated periodontitis similar to amoxicillin plus 
metronidazole, which may be beneficial, where spiramycin is clinically available, for 
patients hypersensitive to amoxicillin or other beta-lactam antibiotics.  Further clinical and 
microbiological studies of spiramycin, particularly in combination with metronidazole, are 
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Abstract    
 
Purpose: Because antimicrobial therapy is often employed in the treatment of infectious 
dental implant complications, this study determined the occurrence of in vitro antibiotic 
resistance among putative peri-implantitis bacterial pathogens.  
 
Materials and methods: Submucosal biofilm specimens were cultured from 160 dental 
implants with peri-implantitis in 120 adults, with isolated putative pathogens identified to 
species level, and tested in vitro for susceptibility to 4 mg/L of doxycycline, 8 mg/L of 
amoxicillin, 16 mg/L of metronidazole, and 4 mg/L of clindamycin. Findings for 
amoxicillin and metronidazole were combined post-hoc to identify peri-implantitis species 
resistant to both antibiotics. Gram-negative enteric rods/pseudomonads were subjected to 
ciprofloxacin disk diffusion testing.   
 
Results: One or more cultivable submucosal bacterial pathogens, most often Prevotella 
intermedia/nigrescens or Streptococcus constellatus, were resistant in vitro to clindamycin, 
amoxicillin, doxycycline or metronidazole in 46.7%, 39.2%, 25%, and 21.7% of the peri-
implantitis subjects, respectively. Only 6.7% subjects revealed submucosal test species 
resistant in vitro to both amoxicillin and metronidazole, which were either S. constellatus 
(one subject) or ciprofloxacin-susceptible strains of gram-negative enteric rods/pseudo-
monads (seven subjects). Overall, 71.7% of the 120 peri-implantitis subjects exhibited 
submucosal bacterial pathogens resistant in vitro to one or more of the tested antibiotics.  
 
Conclusions: Peri-implantitis patients frequently yielded submucosal bacterial pathogens 
resistant in vitro to individual therapeutic concentrations of clindamycin, amoxicillin, 
doxycycline or metronidazole, but only rarely to both amoxicillin and metronidazole. Due 
to the wide variation in observed drug resistance patterns, antibiotic susceptibility testing of 
cultivable submucosal bacterial pathogens may aid in the selection of antimicrobial therapy 











Peri-implantitis is a destructive biological complication affecting dental implants after 
successful intraoral placement and prosthetic restoration (1). Peri-implantitis presents as an 
inflammatory lesion of peri-implant soft and hard tissues, characterized by increased peri-
implant probing depths, bleeding on probing and/or suppuration, progressive peri-implant 
marginal bone loss, and ultimately, dental implant mobility and loss (2,3). Peri-implantitis 
is estimated to occur in 10.7-47.2% of dental implant patients after 10 years of post-
treatment observation (4). A multitude of risk factors have been associated with the onset 
and progression of peri-implantitis, including submucosal presence of various bacterial 
species, Archaea, yeasts, and herpesviruses (5-7); inadequate oral hygiene (2,8); smoking 
(2); excessive occlusal forces (9,10); contamination, corrosion, and residual dental cement 
on submucosal implant surfaces (11,12); history of periodontitis on adjacent natural teeth 
(13); poorly controlled diabetes mellitus (2); and host carriage of IL-1RN gene poly-
morphisms (14).   
 
Because the etiopathogenesis of peri-implantitis is not well delineated, it is not surprising 
that the most effective treatment for peri-implantitis has yet to be conclusively identified 
(15). However, studies and case reports in both animal models and humans have reported 
arrest of peri-implantitis lesions, leading to marked clinical and/or radiographic improve-
ments, when systemic antibiotics were given as adjuncts to mechanical debridement and/or 
surgical procedures on affected dental implants heavily colonized by putative bacterial 
pathogens (16-18). As a result, systemic antibiotic therapy is often advised as a part of peri-
implantitis treatment protocols (19-21), similar to use of systemic antibiotics in 
periodontitis treatment (22), despite an absence to date of strong supporting scientific data 
(23).   
 
Testing subgingival bacterial species for their antibiotic susceptibility is recommended to 
help optimize periodontitis-directed antibiotic drug regimens in order to avoid 
administration of antimicrobial agents to which targeted pathogens are resistant (22). In 
contrast, little attention has been given to this issue in peri-implantitis disease management, 
with most dentists empirically employing antibiotics against peri-implantitis lesions 
without any prior microbiological testing (24). Because relatively few studies to date have 
examined the in vitro antibiotic susceptibility profiles of peri-implantitis-associated 
microorganisms (25-29), the extent to which antibiotic resistance occurs in submucosal 
microbial populations associated with peri-implantitis remains largely unknown. To address 
this need, the present study assessed the occurrence of in vitro antibiotic resistance among 
putative bacterial pathogens isolated from human peri-implantitis lesions. 
 




A retrospective examination of archival records was performed at the Oral Microbiology 
Testing Service (OMTS) Laboratory at Temple University School of Dentistry, 
Philadelphia. A total of 120 partially dentate adults were consecutively identified and 
included in the present study as their peri-implant submucosal plaque samples were 




Each of these adults were diagnosed, in the professional judgment of periodontists in 
private dental practices in the USA, with peri-implantitis (1) on one to five prosthetically 
restored, root-form dental implants, for a total of 160 dental implants, which were 
microbiologically sampled for culture analysis and in vitro antibiotic resistance testing.  
Laboratory records were used to ascertain, as reported by the treating periodontist, the 
geographic location of their private dental practice, and the patient gender, age, current 
smoking habit, peri-implant probing depths, and presence of peri-implant bleeding on 
probing, suppuration, and progressive radiographic marginal bone loss. Independent 
clinical and radiographic evaluations were not performed on the study subjects, and data 
were not available on their ethnicity, systemic medical status, past antibiotic use, oral 
hygiene performance, parafunctional occlusal habits, periodontitis history and treatment, 
and length of time since dental implant prosthetic loading.  The study was approved by the 
Temple University Human Subjects Protections Institutional Review Board, and conducted 
in accordance with ethical principles detailed in the World Medical Association’s 
Declaration of Helsinki, as revised in 2008.   
 
Microbial sampling and transport 
 
Submucosal plaque biofilm specimens were obtained by the diagnosing periodontists, who 
followed a standardized sampling protocol, before treatment from two to five deep peri-
implant probing depths per subject that exhibited bleeding on probing with or without 
suppuration. After isolation with cotton rolls, and removal of saliva and supramucosal 
deposits, one to two sterile, absorbent paper points (Johnson & Johnson, East Windsor, NJ, 
USA) were advanced into each selected peri-implant site for approximately 10 seconds.  
Upon removal, all paper points per study subject were pooled in a glass vial containing six 
to eight small glass beads and 2.0 ml of anaerobically prepared and stored VMGA III 
transport medium (30), which possesses a high preservation capability for oral micro-
organisms during post-sampling transit to the laboratory (30,31). The submucosal samples 
were then transported within 24 hours to the OMTS Laboratory, which is licensed for high 
complexity bacteriological analysis by the Pennsylvania Department of Health. The OMTS 
Laboratory is also federally certified by the USA Department of Health and Human 
Services to be in compliance with Clinical Laboratory Improvement Amendments (CLIA)-
mandated proficiency testing, quality control, patient test management, personnel 
requirements, and quality assurance standards required of clinical laboratories engaged in 
diagnostic testing of human specimens in the USA (32). All laboratory procedures were 
performed following a protocol standardized during the 2006-2012 study time period, and 
by laboratory personnel who were blinded to the clinical status of the study subjects, and 
their inclusion in the present analysis.  
 
Microbial culture and incubation 
 
At the OMTS Laboratory, the specimen vials were warmed to 35ºC to liquefy the VMGA 
III transport medium, and sampled microorganisms were mechanically dispersed from the 
paper points with a vortex mixer, which was used at the maximal setting for 45 seconds.  
Serial, 10-fold dilutions of the dispersed bacteria were prepared in Möller’s VMG I 
anaerobic dispersion solution, comprised of pre-reduced, anaerobically sterilized, 0.25% 
tryptose, 0.25% thiotone E peptone, and 0.5% NaCl (30). Then, 0.1 ml dilution aliquots 
were spread, with a sterile bent glass rod, onto non-selective enriched Brucella blood agar 
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(EBBA) primary isolation plates (33), comprised of 4.3% Brucella agar supplemented with 
0.3% bacto-agar, 5% defibrinated sheep blood, 0.2% hemolyzed sheep red blood cells, 
0.0005% hemin, and 0.00005% menadione, onto Hammond’s selective Campylobacter 
medium (34), and onto selective trypticase soy-bacitracin-vancomycin (TSBV) agar (35).  
EBBA and Hammond’s selective medium plates were incubated at 35ºC for seven days in a 
Coy anaerobic chamber (Coy Laboratory Products, Ann Arbor, MI, USA) containing 85% 





Submucosal test species examined for in this study were Aggregatibacter actino-
mycetemcomitans, Porphyromonas gingivalis, Tannerella forsythia, Prevotella intermedia/ 
nigrescens, Parvimonas micra, Fusobacterium nucleatum, Campylobacter rectus, Strepto-
coccus constellatus, Centipeda periodontii, Staphylococcus aureus, Enterococcus faecalis, 
gram-negative enteric rods/pseudomonads, and Candida species.  
 
Total anaerobic viable counts and counts of  P. gingivalis, T. forsythia, P. intermedia/ 
nigrescens, P. micra, F. nucleatum, S. constellatus, C. periodontii, S. aureus, and E. 
faecalis were made on EBBA primary isolation plates using a ring-light magnifying loupe, 
a dissecting stereomicroscope, and presumptive phenotypic methods previously described 
(36-41). C. rectus was quantitated on Hammond’s medium, and A. actinomycetemcomitans, 
gram-negative enteric rods/pseudomonads, and Candida species on TSBV agar, using 
methods and criteria previously described (33,35,42). The proportional recovery of each 
test species was ascertained in each subject by calculating the percentage of test species 
colony-forming units relative to total submucosal anaerobic viable counts as determined on 
non-selective EBBA primary isolation plates.  
 
In vitro antibiotic resistance testing 
 
Additional 0.1 ml aliquots of submucosal sample dilutions were inoculated onto EBBA 
primary isolation plates supplemented with either 4 mg/L of doxycycline, 8 mg/L of 
amoxicillin, 16 mg/L of metronidazole, or 4 mg/L of clindamycin (all antimicrobials 
obtained as pure powder from Sigma-Aldrich, St. Louis, MO, USA), and incubated 
anaerobically for seven days. These antimicrobial concentrations represent non-susceptible/ 
resistant breakpoint concentrations against anaerobic bacteria for amoxicillin, metro-
nidazole and clindamycin as recommended by the Clinical and Laboratory Standards 
Institute (CLSI) (43), and for doxycycline disk diffusion testing as recommended by the 
French Society for Microbiology (44). Direct colony suspensions (equivalent to a 0.5 
McFarland standard) of pure A. actinomycetemcomitans isolates from selective TSBV 
plates were subcultured onto these media as their recognition is frequently obscured within 
mixed bacterial populations (35). In vitro resistance to the antibiotic breakpoint concentra-
tions of doxycycline, amoxicillin, metronidazole, or clindamycin was recorded when test 
species growth was noted on the respective antibiotic-supplemented EBBA plates 
(33,40,41,45,46). Bacteroides thetaiotaomicron ATCC 29741, Clostridium perfringens 
ATCC 13124, and a multi-antibiotic-resistant clinical periodontal isolate of F. nucleatum 
were employed as positive and negative quality controls for all antibiotic resistance testing 




In vitro data were combined post-hoc for amoxicillin and metronidazole to identify test 
species resistant to both antibiotics (40). A pilot study evaluated the validity of this 
approach using subgingival plaque biofilm samples from 52 subjects with severe chronic 
periodontitis who were not part of the present study. The microbial specimens were 
processed as described above, with inoculation onto EBBA primary isolation plates without 
antibiotics, or supplemented with either 8 mg/L of amoxicillin, 16 mg/L of metronidazole, 
or a combination of both 8 mg/L of amoxicillin and 16 mg/L of metronidazole, followed by 
anaerobic incubation for seven days.   
 
Gram negative enteric rods/pseudomonads recovered on TSBV primary isolation plates 
were subjected to in vitro ciprofloxacin disk diffusion testing, with direct colony 
suspensions of the organisms equivalent to a 0.5 McFarland standard inoculated onto 
Mueller-Hinton agar incubated in ambient air at 35qC for 16-18 hours, and assessed with 




Descriptive analysis was used to characterize the number of dental implants, their arch 
location (maxilla, mandible, or both), and intraoral region (anterior, posterior, or both), per 
each study subject. Submucosal proportions of the test microbial pathogens, and for strains 
exhibiting in vitro antibiotic resistance, were determined for each study subject. Then, the 
occurrence of test species, as well as their mean and median submucosal proportions, was 
tabulated across all subjects, which served as the unit of analysis in the results. Semi-
quantification cut-off values were also applied to microbial proportional recovery data to 
identify peri-implantitis test species and subjects exhibiting moderately heavy (1-10% of 
total cultivable counts) and heavy (> 10%) microbial growth in submucosal plaque biofilm 
specimens, as previously described (48). Kappa analysis, with kappa values > 0.75 
indicative of excellent agreement (49), quantified agreement in the pilot study data between 
test species growth on EBBA plates jointly supplemented with both amoxicillin and 
metronidazole, as compared to a post-hoc combination of data from EBBA plates 
individually supplemented with amoxicillin or metronidazole. Data analysis was performed 





The 120 peri-implantitis subjects included 66 men and 54 women, aged 28-90 years (mean 
60.9 r 10.3 (SD) years), and 11.7% current smokers. A total of 80 (66.7%) of the study 
subjects geographically originated from dental practices in Maryland (n = 16), 
Pennsylvania (n = 30), New Jersey (n = 28), Virginia (n = 2), and New York (n = 4) in the 
mid-Atlantic region of the USA, with all others from six other states in the eastern USA (n 
= 32), and four western states (n = 8).   
 
Table 1 provides the intraoral subject distribution of the 160 microbiologically sampled 
dental implants, which were made by either Biomet 3i (23.1%), Nobel Biocare (22.5%), 
BioHorizons (18.8%), Bicon 11.9%, or an undisclosed manufacturer (23.7%). In most 
study subjects (60.8%), a single dental implant with peri-implantitis was sampled, with 
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most located in posterior areas of the oral cavity, and similarly distributed between the 
maxilla and mandible (Table 1).   
 
The sampled dental implants were reported by the diagnosing periodontists to have deep   
(> 6 mm) probing depths (mean 7.7 ± 0.2 (SE) mm), bleeding on probing, and progressive 
radiographic marginal bone loss. For 16 (13.3%) of the study subjects, suppuration was 
noted at the sampled dental implants.          
 
Submucosal biofilm specimens from the study subjects averaged total anaerobic viable 
counts of 6.9 x 107 ± 8.4 x 106 (SE) organisms/ml of sample (range = 5.0 x 106 to 3.5 x 108 
organisms/ml) on non-selective EBBA primary isolation plates. All study subjects yielded 
either heavy (75% subjects) or moderately heavy (25% subjects) submucosal growth by one 
or more of the bacterial test species. 
 
Table 2 lists the occurrence and proportional cultivable recovery of submucosal test species 
from the study subjects. P. micra, F. nucleatum, and P. intermedia/nigrescens were the 
most frequent test species isolated, with heavy or moderately heavy submucosal growth of 
these organisms found in 83-100% of culture-positive subjects. Gram-negative enteric 
rods/pseudomonads, identified to a species level in one subject as Escherichia coli, 
exhibited heavy or moderately heavy submucosal growth in seven subjects. Candida 
species were recovered from four subjects in relatively low submucosal proportions (mean 
0.2%). No submucosal S. aureus or E. faecalis were detected with the non-selective culture 
media used in the study.  
 
For subgingival microbial samples processed in the pilot study (Table 3), 195 of 198 
(98.5%) test species demonstrated excellent agreement (kappa value = 0.79 r 0.11 (SE)) 
between their in vitro growth on EBBA plates jointly supplemented with both amoxicillin 
and metronidazole, and their growth patterns as determined from a post-hoc combination of 
in vitro resistance data from EBBA plates individually supplemented with amoxicillin or 
metronidazole. Based on this, in vitro antibiotic resistance data from amoxicillin and 
metronidazole-supplemented EBBA primary isolation plates were combined post-hoc for 
subjects with peri-implantitis. 
   
Table 4 lists the occurrence of in vitro antibiotic resistance among peri-implantitis bacterial 
test species. P. micra and F. nucleatum rarely exhibited in vitro resistance to any of the test 
antibiotics. C. rectus and C. periodontii were sensitive to all of the test antibiotic 
concentrations. P. gingivalis was similarly susceptible, except for four subject strains 
resistant in vitro to clindamycin. P. intermedia/nigrescens revealed little or no in vitro 
resistance to doxycycline or metronidazole, but was resistant to amoxicillin among 38 
subject strains, and to clindamycin in 35 subject strains, with antibiotic-resistant strains 
averaging 6.6% and 4.3%, respectively, of submucosal viable counts. T. forsythia similarly 
showed in vitro resistance to amoxicillin in six subject strains, and to clindamycin among 
seven subject strains. Most S. constellatus subject strains (18 out of 24) were resistant in 
vitro to metronidazole, with nine resistant to doxycycline, two resistant to amoxicillin, and 
18 resistant to clindamycin. Antibiotic-resistant S. constellatus strains averaged 4-18.6% of 
cultivable submucosal organisms in culture-positive subjects. All submucosal gram-
negative enteric rods/pseudomonads were resistant in vitro to doxycycline, amoxicillin, 




diffusion testing. All six A. actinomycetemcomitans subject strains exhibited in vitro 
resistance to clindamycin, and five to doxycycline, whereas none were resistant in vitro to 
either amoxicillin or metronidazole (Table 4). 
 
When in vitro data for amoxicillin and metronidazole were combined post hoc (Table 4), 
one S. constellatus subject stain (also resistant to doxycycline), and all gram-negative 
enteric rods/pseudomonads, were resistant to both antibiotic concentrations.   
 
Among the seven study subjects with ciprofloxacin-susceptible, submucosal strains of 
gram-negative enteric rods/pseudomonads, two subjects yielded only gram-negative enteric 
rods/pseudomonads from their submucosal biofilm specimens, and three subjects 
additionally had moderate to heavy growth of co-colonizing metronidazole-susceptible test 
species (including P. gingivalis, P. intermedia/nigrescens, P. micra, C. rectus and F. 
nucleatum). In two other study subjects, one additionally had moderately heavy P. micra 
growth resistant in vitro to both metronidazole and doxycycline, whereas the other study 
subject additionally revealed moderate growth of metronidazole-susceptible test species 
(including P. intermedia/nigrescens, P. micra, C. rectus and T. forsythia), as well as 
moderate growth of metronidazole-resistant S. constellatus and F. nucleatum (which was 
also resistant in vitro to doxycycline). In the latter study subject, all of the test species 
accompanying the gram-negative enteric rods/pseudomonads were susceptible in vitro to 
clindamycin.      
 
Table 5 presents the occurrence of one or more antibiotic-resistant peri-implantitis bacterial 
pathogens in the study subjects. A total of 46.7% of subjects with peri-implantitis yielded 
clindamycin-resistant bacterial test species. In comparison, 39.2%, 25% and 21.7% of 
subjects had submucosal bacterial test species resistant in vitro to amoxicillin, doxycycline, 
and metronidazole, respectively. In addition, 6.7% subjects with peri-implantitis harbored 
submucosal bacterial test species resistant in vitro to both amoxicillin at 8 mg/L and 
metronidazole at 16 mg/L (Table 4). Overall, 86 (71.7%) of the 120 subjects with peri-
implantitis exhibited submucosal bacterial pathogens resistant in vitro to one or more of the 
test antibiotics, whereas 34 (28.3%) study subjects did not reveal any peri-implantitis 
bacterial test species resistant in vitro to any of the evaluated antibiotics. 
 
In the four study subjects with sparse submucosal growth of Candida species, which were 
resistant in vitro to all of the test antibiotics, none of their recovered bacterial test species 



























Table 1.  Intraoral distribution of peri-implantitis-affected  




No. (%) of 
study subjects 
  
  Implants/subject  
       one 73 (60.8) 
       2-3 32 (26.7) 
       4-5 15 (12.5) 
  
  Arch location  
       maxilla 56 (46.7) 
       mandible 52 (43.3) 
       both 12 (10.0) 
  
  Intraoral region  
       anterior 25 (20.8) 
       posterior 76 (63.3) 





































































   
   
   
   































































































































































































































































































































































































































































































































































































































































































   
   
   
   

















































   
   
   
   

















































   
   
   
   























































































































































































































   
  




































































































































































































































































































































































































































   
   
   
   



























































































































































































































































































































































































































































































































































































































































































































Table 5.  Occurrence of antibiotic-resistant submucosal  
                pathogens in 120 subjects with peri-implantitis. 
a Post-hoc combination of in vitro resistance data for  









No. (%) of subjects with 
SXWDWLYHSHUL-
implantitis bacterial 
pathogens resistant  
in vitro to 
 antibiotic breakpoint 
concentrations 
  
clindamycin (4 mg/L) 56 (46.7) 
amoxicillin (8 mg/L) 47 (39.2) 
doxycycline (4 mg/L) 30 (25.0) 
metronidazole (16 mg/L) 26 (21.7) 
amoxicillin (8 mg/L) + 







All of the subjects with peri-implantitis in this study yielded heavy or moderately heavy 
submucosal growth by one or more of the bacterial test species. This suggests a potential 
contributing role for these microbial species in the pathogenesis of the evaluated peri-
implantitis lesions, and supports a possible role for antimicrobial agents in their therapeutic 
management. As a result, assessment of their antibiotic susceptibility profile in vitro is 
clinically relevant.   
 
The frequent submucosal occurrence in this study of P. micra, F. nucleatum, and P. 
intermedia/nigrescens, as well as the recovery of C. rectus, T. forsythia, P. gingivalis, S. 
constellatus, A. actinomycetemcomitans, and gram-negative enteric rods/pseudomonads, is 
consistent with previous culture-based investigations of human peri-implantitis (5). These 
species have also been implicated as putative pathogens in the pathogenesis of periodontitis 
(33,37,42,50). Additional bacterial species and novel phylotypes may be identified in peri-
implantitis lesions with other types of selective culture media (37,38), and with various 
nucleic acid-based molecular methods, such as checkerboard DNA-DNA hybridization 
(51), end-point and real-time PCR (52,53), denaturing gradient gel electrophoresis (54,55), 
and 16S ribosomal RNA sequencing (56,57). It is not known from the present retrospective 
study design if these organisms initiated peri-implantitis similar to periodontitis, or merely 
colonized deep peri-implant probing depths secondarily after other etiologic factors 
triggered the onset of peri-implant marginal tissue breakdown.   
 
Nevertheless, the purpose of the present study was to assess the occurrence of in vitro 
antibiotic resistance among cultivable bacterial pathogens in human peri-implantitis lesions. 
In this regard, over 70% of the peri-implantitis study subjects yielded submucosal bacterial 
pathogens resistant in vitro to therapeutic concentrations of one or more of clindamycin, 
doxycycline, amoxicillin, or metronidazole alone, or to both amoxicillin and metronidazole. 
This suggests that patients with peri-implantitis in the USA frequently harbor submucosal 
bacterial pathogens resistant to several antibiotics commonly employed in clinical dental 
and periodontal practice.   
 
The highest subject frequency (46.7%) of in vitro antibiotic resistance among submucosal 
bacterial pathogens was to clindamycin, particularly in strains of P. intermedia/nigrescens, 
T. forsythia, and A. actinomycetemcomitans. Amoxicillin submucosal bacterial pathogen 
resistance was detected in 39.2% of subjects with peri-implantitis, most notably in P. 
intermedia/nigrescens, which is often positive for amoxicillin-GHJUDGLQJ ȕ-lactamase 
enzyme production (41,58). Doxycycline and metronidazole bacterial pathogen resistance 
was observed in 25% and 21.7% of subjects with peri-implantitis, respectively, most often 
among S. constellatus submucosal isolates. Interestingly, since metronidazole in the 
presence of titanium shows enhanced antimicrobial activity in vitro against P. gingivalis 
and P. intermedia biofilms (59), it is possible that similar improved drug effects may occur 
in vivo and potentially lessen metronidazole resistance in bacterial biofilms colonizing 
titanium dental implant surfaces.      
 
The relatively low subject frequency (6.7%) in subjects of peri-implantitis bacterial path-
ogen resistance to both amoxicillin and metronidazole was similar to that found among 
subgingival bacterial pathogens in chronic periodontitis (40), and is consistent with reports 
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of improved peri-implantitis clinical and radiographic parameters following systemic 
administration of the combination of amoxicillin and metronidazole (18). Sbordone et al. 
(25) also found amoxicillin plus metronidazole to be highly active in vitro against peri-
implantitis isolates of P. gingivalis, P. intermedia, and F. nucleatum. These findings 
suggest that the effects of adjunctive amoxicillin plus metronidazole in peri-implantitis 
treatment may mirror the drug combination’s efficacy in enhancing periodontitis therapy 
(60,61).  
  
It is noteworthy that submucosal S. constellatus in one subject, and gram-negative enteric 
rods/pseudomonads in seven subjects, were resistant in vitro to both amoxicillin at 8 mg/L 
and metronidazole at 16 mg/L. The relatively high submucosal levels of these multidrug-
resistant organisms in species-positive subjects (Table 3) argue against administration of 
amoxicillin plus metronidazole in colonized patients with peri-implantitis. In considering 
alternative antimicrobial regimens, it is important to take into account the antimicrobial 
susceptibility of other co-colonizing bacterial pathogens within peri-implantitis lesions.  
Submucosal gram-negative enteric rods/pseudomonads in all seven species-positive study 
subjects were sensitive in vitro to ciprofloxacin, which exerts only weak activity against 
oral anaerobic bacteria (62). Three of these subjects also yielded species of metronidazole- 
susceptible anaerobic bacterial pathogens, whereas two other subjects revealed clindamycin 
susceptible bacterial pathogens, which were otherwise resistant in vitro to the other test 
antibiotics. Thus, for these latter two types of submucosal biofilm profiles, the use of 
ciprofloxacin plus metronidazole, or ciprofloxacin plus clindamycin, for adjunctive drug 
therapy may be more appropriate to consider than ciprofloxacin alone (22). This illustrates 
the variability of antibiotic susceptibility patterns that may occur in mixed facultative-
anaerobic bacterial pathogen populations on ailing dental implants, and the potential 
complexities faced by clinicians contemplating selection and administration of peri-
implantitis antimicrobial therapies.       
 
While the present study evaluated, to date, the largest number of human subjects with peri-
implantitis (n = 120) for in vitro antibiotic resistance among cultivable submucosal putative 
bacterial pathogens, it is important to appreciate several limitations in its retrospective 
study design. First, the study subjects embodied a private dental practice-based 
convenience sample that may not be statistically representative of peri-implantitis patients 
in the USA or other countries. This limits the generalizability of the present study findings 
to other peri-implantitis patient populations, which may possess geographic-based 
differences in antibiotic susceptibility patterns among oral bacterial species (46,63).  
Because no clinical or radiographic evaluations were conducted by calibrated examiners 
independent of the private practice periodontists who submitted submucosal biofilm 
specimens for microbiological testing, the diagnosis of peri-implantitis in the study subjects 
may be questioned. While the private practice periodontists were not formally calibrated in 
their classification of peri-implantitis, their identification of deep peri-implant probing 
depths (mean 7.7 mm) exhibiting bleeding on probing and/or suppuration and progressive 
marginal bone loss is consistent with recognized criteria for peri-implantitis (1), and 
correlates with data demonstrating a statistically significant odds ratio of 4.6 between peri-
LPSODQWSURELQJGHSWKVPPDQGDKLVWRU\RIPDUNHGSURJUHVVLYHPDUJLQDOERQHORVVRQ
prosthetically-restored dental implants (64). Because information was also not accessible 
for the study subjects on their ethnicity, systemic medical status, past antibiotic use, oral 




and length of time since dental implant prosthetic loading, the potential influence of these 
variables on the observed in vitro antibiotic resistance patterns could not be evaluated, and 
remains to be delineated.   
 
In addition, exact minimal inhibitory concentration values of the test antimicrobials against 
the peri-implantitis bacterial pathogens were not determined with the clinical laboratory 
methods followed, and the molecular genetic basis for the detected peri-implant bacterial 
drug resistance was not elucidated. However, the direct plating method used in this study to 
detect antibiotic resistance on primary culture plates has been employed in previous 
periodontal microbiology studies (33,40,41,45,46), and correlates well (r2 = 0.99) with the 
CLSI-approved agar dilution susceptibility assay in identifying antibiotic-resistant 
periodontal microorganisms (45). Similarly, a 94% agreement rate has been reported 
between primary (direct) versus secondary (subculture) antibiotic susceptibility plate 
testing on acute dentoalveolar abscess bacterial isolates (65). Indeed, identification of 
submucosal bacterial pathogens resistant to internationally-recognized therapeutic 
breakpoint concentrations of antibiotics being considered in peri-implantitis therapy, 
irrespective of the exact minimal inhibitory drug concentration values against the 
organisms, is highly relevant and clinically practical to treating dentists seeking to enhance 
their antimicrobial drug selections for patients.  
 
However, because antibiotic susceptibility findings in vitro do not necessarily by 
themselves confer drug effectiveness in vivo against targeted bacterial pathogens (66), the 
extent to which the reported laboratory findings may potentially impact the treatment of 
human peri-implantitis lesions is not known. Additional variables influencing the success of 
antimicrobial therapy in clinical settings need to be considered, such as the ability of 
patients to safely take medications (i.e., no contraindicating allergies, drug interactions or 
side effects), differences among patients in oral antibiotic absorption (67), drug passage 
through peri-implant tissues, antibiotic penetration into antimicrobial-resistant submucosal 
bacterial biofilms (68), and patient compliance with prescribed drug dosing schedules.  
However, it is generally recognized that drugs lacking antimicrobial efficacy against 
targeted microorganisms under in vitro laboratory testing conditions are unlikely to be 
effective therapeutic agents in vivo against the organisms (69). Additional research is 
needed to address these issues specific to patients with dental implants, and to further 




A relatively wide range of in vitro antibiotic resistance was found among putative bacterial 
pathogens recovered from submucosal surfaces of 160 dental implants in 120 patients 
suffering from peri-implantitis. The highest frequency of in vitro antibiotic submucosal 
bacterial pathogen resistance in subjects with peri-implantitis was to clindamycin, whereas 
joint resistance to amoxicillin plus metronidazole was rare. No single antibiotic or 
antibiotic combination tested in vitro showed complete inhibition of peri-implantitis 
bacterial pathogens across all of the study subjects. These findings suggest that 
microbiological analysis and in vitro antibiotic susceptibility testing of cultivable isolates 
may aid in the selection of appropriate antimicrobial treatment regimens for peri-
implantitis.  
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The research findings presented in this thesis add to the scientific database that underlies 
the clinical application of systemic antibiotics in periodontal disease and peri-implantitis 
management. It is clear from the various studies described in Chapters 2-7 that there is 
considerable variability in the antibiotic susceptibility of the evaluated putative bacterial 
pathogens in human chronic periodontitis and peri-implantitis patients in the United States.  
From available data, it appears that the occurrence of antibiotic-resistant periodontal and 
peri-implant bacterial pathogens is greater than levels reported in northern European 
countries, but likely less than in South America. It is also clear that assertions about the 
predictability of antimicrobial profiles of putative periodontal pathogens, which led to 
conclusions about a perceived lack of benefit for antimicrobial susceptibility testing (1), do 
not appear to be applicable to periodontitis and peri-implantitis patients in the United 
States, since considerable resistance was found to several antibiotics among subgingival 
and submucosal clinical isolates. However, the present thesis research findings confirm that 
the combination of amoxicillin plus metronidazole, which have complementary and 
sometimes synergistic antimicrobial spectrums, encounter the lowest occurrence of 
antibiotic-resistant bacterial pathogens among the tested antibiotics. Further research is 
needed to gain more insight into the use of this antibiotic drug combination in dentistry, and 
why some periodontitis patients fail to experience clinical benefits with it.     
 
Because of the lack of geographic-based data, there is a pressing need for the development 
of national and international surveillance systems to track antibiotic resistance in bacterial 
species important in periodontitis and peri-implantitis, with the occurrence of new 
outbreaks of drug resistance, and trends in antibiotic resistance patterns, used to help 
clinical patient care and influence policy on antibiotic use. No such organized surveillance 
system exists in the world today relative to dental-based infections, despite the increasing 
world-wide use of antibiotics in periodontal disease, peri-implantitis, and other oral disease 
treatments.       
 
The antibiotic resistance variability observed in the present thesis research has important 
treatment implications for clinicians attempting to successfully treat patients with 
antibiotic-resistant pathogens, since an increased risk of clinical treatment failure is 
expected if an antibiotic to which the patient’s pathogenic microbiota is resistant is 
empirically selected and administered. Thus, a more appropriate treatment planning 
strategy for clinical use is to base systemic periodontal and peri-implantitis antibiotic 
therapy selection in part on the results of in vitro antibiotic susceptibility testing of 
cultivable pathogens that are associated with the patient’s subgingival or submucosal dental 
plaque biofilm. This information would augment the more conventional risk-benefit 
considerations involving the patient’s medical status, concurrent medication use, and 
potential antibiotic drug side-effects. Access to in vitro antibiotic resistance test results 
would enable clinicians to earlier consider alternative antibiotic choices when confronted 
with antibiotic resistance before the patient suffers a clinical treatment failure. 
 
Since antibiotic susceptibility testing presently requires viable microorganisms to perform, 
it is necessary to rely upon cultivation procedures in carrying out microbiological analysis 
of subgingival and submucosal bacterial populations. Because of the specialized nature of 
the subgingival and submucosal bacterial populations, only a limited number of laboratories 




this resource may even become scarcer as the present laboratory directors approach 
retirement without a new generation in waiting.     
 
In the future, detection of antibiotic-resistant bacterial pathogens may be potentially 
identified without cultivation by use of molecular methods seeking the presence of 
functional antibiotic resistance genes, but such approaches remain at present, only 
theoretical. 
 
Prime candidates for systemic periodontal antibiotic therapy are periodontitis patients not 
adequately responding to local mechanical-surgical periodontal therapy, or who have a 
history of recurrent or progressive periodontitis disease-activity despite the provision of 
thorough root instrumentation, meticulous patient supragingival plaque control, and regular 
periodontal maintenance care. The diversity of the subgingival microbiota in these types of 
periodontitis patients is often highlighted by multiple species with varying antibiotic 
susceptibilities, which pose problems for clinicians attempting to empirically select 
antibiotic therapies. For patients with dental implant complications of apparent infectious 
origin, systemic antibiotics may be prescribed as an adjunct to surgical procedures aimed at 
mechanical disruption of submucosal bacterial biofilms, and disinfection of dental implant 
surfaces exposed to the oral environment. At present, no systemic antibiotic therapy is 
indicated for patients with gingivitis, mild forms of periodontitis, and peri-implant 
mucositis. 
 
Future studies are urgently needed to better determine the optimum doses and durations for 
systemic antibiotic therapies in dentistry. At present, a wide variety of antibiotic drug 
schedules are prescribed for patients with periodontitis and peri-implantitis, and concern 
exists that suboptimal antibiotic concentrations may compromise patient outcomes, and 
potentially contribute to increased antibiotic resistance in the bacteria in the oral cavity and 
other body sites. 
 
The molecular basis for the antibiotic resistance detected in this thesis also needs to be 
assessed in future studies to help better understand the process by which antibiotic 
resistance genes are transferred among bacterial species, and disseminated in human 
population groups. 
 
Despite the occurrence of antibiotic resistance among subgingival and submucosal bacterial 
pathogens, periodontal and peri-implantitis antibiotic-based treatments nevertheless have 
the potential to be more effective, predictable, and safe for patients if more emphasis is 
placed on the increased use of microbiological analysis, and antibiotic susceptibility testing, 
as a routine part of dental treatment planning. 
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Antibiotics play a key role in anti-infective treatment strategies directed against destructive 
periodontal diseases and infectious dental implant complications. As disease processes 
driven by the growth of specific pathogenic bacterial populations on subgingival tooth roots 
and submucosal dental implant surfaces, periodontitis and peri-implantitis exhibit clinical 
and radiographic improvements characteristic of a health-associated status when marked 
suppression or eradication of periodontal and peri-implant bacterial pathogens occurs with 
appropriate systemic antibiotic therapy administered in conjunction with mechanical 
debridement and plaque control procedures. However, an important determinant in the 
potential success of systemic periodontal and peri-implantitis antibiotic therapy is the 
occurrence of antibiotic resistance among targeted periodontal and peri-implant bacterial 
pathogens, which may survive antibiotic drug regimens and contribute to clinical treatment 
failure. Consequently, this thesis focused on assessing the extent of in vitro resistance 
within selected putative periodontal and peri-implant bacterial species, and among groups 
of chronic periodontitis and peri-implantitis patients, to several antibiotics frequently used 
in periodontal and oral implantology dental practice. 
 
Chapter 1 provides an overview of the pathogenesis of chronic periodontitis and peri-
implantitis, the key role systemic drug administration may play in the arrest of the diseases, 
and unresolved issues pertaining to the optimization of systemic periodontal and peri-
implant antibiotic therapy. 
 
Chapter 2 examines the in vitro antibiotic susceptibility profiles of Streptococcus 
constellatus and Streptococcus intermedius, often overlooked gram-positive periodontal 
pathogens that have been associated with refractory periodontitis patients. The in vitro 
inhibition of amoxicillin, azithromycin, clindamycin, ciprofloxacin, doxycycline, and 
metronidazole was evaluated on the largest number to date (n = 50 total) of S. constellatus 
and S. intermedius fresh clinical isolates of subgingival origin recovered from chronic 
periodontitis subjects. Using E-test susceptibility methodology to determine minimal 
inhibitory concentration (MIC) values, and Clinical and Laboratory Standards Institute 
(CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
antibiotic susceptibility breakpoint concentrations and interpretative standards, clindamycin 
was identified as the most active test antibiotic against S. constellatus (MIC90 = 0.25 
mg/L), with amoxicillin most active against S. intermedius (MIC90 = 0.125 mg/L).  30% of 
the S. constellatus and S. intermedius clinical isolates were resistant in vitro to doxycycline, 
98% were intermediate in susceptibility to ciprofloxacin, and 90% were resistant to 
metronidazole at 16 mg/L. It was concluded that the variable antibiotic susceptibility 
profiles of subgingival S. constellatus and S. intermedius may complicate selection of 
periodontitis antibiotic therapy in species-positive patients, and that microbiological 
analysis encompassing antimicrobial sensitivity testing may be particularly helpful in 
periodontal treatment planning for refractory periodontitis patients. 
 
Chapter 3 assesses the in vitro antibiotic susceptibility profiles of periodontal isolates of 
Enterococcus faecalis, an opportunistic gram-positive pathogen that may be recovered in 
periodontitis patients responding poorly to mechanical forms of periodontal therapy. Broth 
microdilution susceptibility panels, and CLSI criteria and interpretative guidelines, were 




faecalis clinical isolates (n = 47) tested to date from chronic periodontitis patients in the 
United States. Periodontal E. faecalis clinical isolates exhibited substantial in vitro 
resistance to tetracycline (53.2% resistant), erythromycin (80.8% resistant or intermediate 
resistant), clindamycin (100% resistant to 2 mg/L), and metronidazole (100 % resistant to 4 
mg/L). In contrast, subgingival E. faecalis was generally sensitive to ciprofloxacin (89.4% 
susceptible; 10.6% intermediate resistant), and 100% susceptible in vitro to ampicillin, 
amoxicillin/clavulanate, vancomycin, and teicoplanin. These findings suggest that, among 
the evaluated antibiotics with oral administration routes, heavy E. faecalis growth in 
periodontal pockets of periodontitis patients may best respond to systemic antibiotic 
therapy involving ampicillin, amoxicillin/clavulanate, or ciprofloxacin, whereas tetracy-
cline, erythromycin, clindamycin, and metronidazole would likely be ineffective 
therapeutic agents against this species. 
 
Chapter 4 DGGUHVVHVWKHH[WHQWWRZKLFKEDFWHULDOȕ-lactamase enzyme production, which 
KDV WKH FDSDELOLW\ WR K\GURO\]H DPLGH ERQGV RI ȕ-lactam antibiotics and render them 
pharmacologically inactive, occurs within the subgingival microbiota of chronic 
periodontitis patients. The largest group of chronic periodontitis subjects to date were 
HYDOXDWHG IRU VXEJLQJLYDO ȕ-lactamase-producing bacteria (n = 564), which was detected 
test species growth on enriched Brucella blood agar primary isolation plates supplemented 
with amoxicillin alone, and their absence on similar primary isolation plates containing 
ERWK DPR[LFLOOLQ SOXV FODYXODQLF DFLG D SRWHQW ȕ-lactamase enzyme inhibitor. 
Approximately one-KDOI  RI WKH VWXG\ VXEMHFWV \LHOGHG ȕ-lactamase enzyme 
producing subgingival bacterial test species, with Prevotella intermedia/nigrescens, 
Fusobacterium nucleatum, and other Prevotella VSHFLHV PRVW IUHTXHQWO\ LGHQWLILHG DV ȕ-
lDFWDPDVHHQ]\PHSURGXFLQJRUJDQLVPV,QDGGLWLRQQHDUO\DOORIWKHȕ-lactamase 
enzyme producing bacterial test species strains recovered were susceptible in vitro to 
metronidazole at 4 mg/L. These findings raise questions about the therapeutic potential of 
single-GUXJ UHJLPHQVZLWK ȕ-lactam antibiotics in periodontal therapy. In addition, the in 
vitro HIIHFWLYHQHVV RI PHWURQLGD]ROH DJDLQVW QHDUO\ DOO UHFRYHUHG ȕ-lactamase enzyme 
producing subgingival bacterial species suggests its value in protecting against amoxicillin 
GHJUDGDWLRQE\ ȕ-lactamase enzymes in systemic periodontal antibiotic therapy involving 
the combination of amoxicillin plus metronidazole. 
  
Chapter 5 focuses on the occurrence of in vitro antibiotic resistance among selected 
subgingival periodontal pathogens in chronic periodontitis subjects, and assessed the largest 
number of chronic periodontitis subjects in the United States (n = 400) for in vitro 
antibiotic testing of subgingival periodontal pathogens in 20 years. Utilizing subgingival 
biofilm specimens from untreated inflamed and deep periodontal pockets, selected 
cultivable periodontal pathogens were tested on antibiotic-supplemented primary isolation 
plates in vitro for susceptibility to breakpoint concentrations of amoxicillin at 8 mg/L, 
clindamycin at 4 mg/L, doxycycline at 4 mg/L, and metronidazole at 16 mg/L, with gram-
negative enteric rods/pseudomonads additionally subjected to ciprofloxacin disk diffusion 
testing. It was revealed that 74.2% of the chronic periodontitis subjects had subgingival 
periodontal pathogens resistant to at least one of the test antibiotics. Test species, most 
often P. intermedia/nigrescens, S. constellatus or Aggregatibacter actinomycetemcomitans, 
were resistant in vitro to doxycycline, amoxicillin, metronidazole, or clindamycin, in 55%, 
43.3%, 30.3%, and 26.5% of the chronic periodontitis subjects, respectively. 15% of 




metronidazole, which were mostly either S. constellatus or ciprofloxacin-susceptible strains 
of gram-negative enteric rods/pseudomonads. These findings indicate that chronic 
periodontitis subjects in the United States frequently yielded subgingival periodontal 
pathogens resistant in vitro to therapeutic concentrations of antibiotics, and demonstrated a 
wide variability in periodontal pathogen antibiotic resistance patterns. This frequent 
occurrence of, and considerable variability in, periodontal pathogen antibiotic resistance  
should concern clinicians empirically selecting antibiotic treatment regimens for chronic 
periodontitis patients, and suggests an important role for microbiological analysis and 
antibiotic susceptibility testing as an aid in the selection of systemic periodontal antibiotic 
therapy.      
 
Chapter 6 determined the occurrence of in vitro resistance to therapeutic concentrations of 
spiramycin, a macrolide antibiotic often overlooked in periodontal chemotherapeutics, as 
well as amoxicillin and metronidazole, among subgingival periodontal pathogens in chronic 
periodontitis patients in the United States. Selected cultivable periodontal pathogens from 
37 chronic periodontitis subjects were tested on antibiotic-supplemented primary isolation 
plates in vitro for susceptibility to breakpoint concentrations of spiramycin at 4 mg/L, 
amoxicillin at 8 mg/L, and metronidazole at 16 mg/L, with test results combined post-hoc 
for spiramycin and metronidazole, and for amoxicillin and metronidazole, to determine the 
number and proportion of organism-positive study subjects where test putative periodontal 
pathogens exhibited in vitro resistance to both antibiotics.  Test periodontal pathogens were 
resistant in vitro to spiramycin, amoxicillin, or metronidazole in 48.7%, 62.2%, and 27% of 
the chronic periodontitis subjects, respectively. Spiramycin in vitro resistance occurred 
mostly among species of F. nucleatum (44.4% of organism-positive subjects), with less 
frequent resistance, approximating 10% or less of subject strains, found among clinical 
isolates of P. intermedia/ nigrescens, Parvimonas micra, S. constellatus, S. intermedius, 
Porphyromonas gingivalis, and Tannerella forsythia. Only one subject harbored sub-
gingival periodontal pathogens resistant to both spiramycin and metronidazole, which were 
S. constellatus and S. intermedius strains. Similarly, only one subject yielded any test 
species resistant in vitro to both amoxicillin and metronidazole, which also were strains of 
S. constellatus. These finding suggest that with one-half of chronic periodontitis subjects 
demonstrating in vitro spiramycin resistance among subgingival periodontal pathogens, 
particularly F. nucleatum species, spiramycin by itself appears to have only a limited 
potential as a systemic chemo-therapeutic agent in human periodontitis therapy. However, 
in vitro resistance patterns also suggest that therapeutic concentrations of spiramycin plus 
metronidazole may have potential antimicrobial efficacy in non-A. actinomycetemcomitans-
associated periodontitis patients similar to amoxicillin plus metronidazole, and may be 
beneficial for patients hypersensitive to amoxicillin or other beta-lactam antibiotics.    
 
Chapter 7 evaluates the occurrence of in vitro antibiotic resistance among putative peri-
implantitis bacterial pathogens in the largest number of human peri-implantitis subjects 
studied to date (n = 120) on this issue. Submucosal biofilm specimens were cultured from 
160 dental implants with peri-implantitis in 120 adults, with isolated putative pathogens 
tested on antibiotic-supplemented primary isolation plates for susceptibility to doxycycline 
at 4 mg/L, amoxicillin at 8 mg/L, metronidazole at 16 mg/L, and clindamycin at 4 mg/L, 
with gram-negative enteric rods/pseudomonads additionally subjected to ciprofloxacin disk 
diffusion testing. Test results for amoxicillin and metronidazole were combined post-hoc to 




peri-implantitis subjects yielded submucosal bacterial pathogens resistant in vitro to one or 
more of the test antibiotics. Cultivable submucosal bacterial pathogens, most often P. 
intermedia/nigrescens or S. constellatus, were resistant in vitro to clindamycin, amoxicillin, 
doxycycline or metronidazole in 46.7%, 39.2%, 25%, and 21.7% of the peri-implantitis 
subjects, respectively. Only 6.7% subjects revealed submucosal test species resistant in 
vitro to both amoxicillin and metronidazole, which were either S. constellatus or 
ciprofloxacin-susceptible strains of gram-negative enteric rods/pseudomonads. These 
findings indicate that peri-implantitis patients frequently harbor submucosal bacterial 
pathogens resistant in vitro to individual therapeutic concentrations of clindamycin, 
amoxicillin, doxycycline or metronidazole, but only rarely to both amoxicillin and metro-
nidazole. Due to this wide variation in antibiotic resistance patterns, antibiotic susceptibility 
testing of cultivable submucosal bacterial pathogens may aid in the selection of 
antimicrobial therapy for peri-implantitis patients.     
 
Chapter 8 offers additional perspective on the above research findings relative to their 
potential clinical diagnostic implications and therapeutic applications in clinical periodontal 
and oral implantology practice. It is concluded that microbiological analysis encompassing 
evaluation of the antibiotic susceptibility of targeted pathogens offers practicing clinicians 
an enhanced ability to optimize selection and administration of systemic periodontal and 
peri-implantitis antibiotic therapies, and to reduce the risk of clinical failures due to the 
presence of antibiotic-resistant pathogenic bacterial species.  Specific clinical recommenda-
tions are offered as to how to implement this approach into modern oral health care 
practice. Directions for future research on the use of systemic antibiotics in the treatment of 
destructive periodontal diseases and infectious dental implant complications are also 








































Antibiotica spelen een belangrijke rol bij de behandeling van infectieuze, destructieve 
vormen van parodontale aandoeningen en infecties rond tandvervangende implantaten. Bij 
deze aandoeningen spelen subgingivale bacteriële populaties op het worteloppervlak en op 
het oppervlak van het submucosale implantaat een belangrijke rol. Reductie van de 
bacteriële biofilm op deze oppervlakken is essentieel voor klinische en radiologische 
verbeteringen van de parodontale en peri-implantaire status. Naast de mechanische reductie 
van de bacteriële biofilm kan een systemische antibioticum behandeling of het toepassen 
van een combinatie van antibiotica een belangrijke bijdrage leveren aan de reductie van de 
subgingivale en de submucosale pathogene bacteriën. Een goed mondhygiëneniveau is 
hierbij van groot belang. Echter, een belangrijke determinant voor het succes van een 
systemische antibioticum therapie bij parodontale en peri-implantaire infecties is de 
aanwezigheid van antibioticum resistentie bij parodontale en peri-implantaire bacteriële 
pathogenen die niet onderdrukt worden en zo een bijdrage kunnen leveren aan een 
verminderde therapieresponse. Dit proefschrift beschrijft onderzoek naar het voorkomen 
van in vitro resistentie bij geselecteerde parodontale en peri-implantaire bacteriesoorten in 
patiënten met chronische parodontitis en patiënten met peri-implantitis. In dit onderzoek 
zijn antibiotica onderzocht die regelmatig worden toegepast bij de behandeling van 
parodontitis en peri-implantaire infecties.  
 
In Hoofdstuk 1 wordt de pathogenese van parodontitis en peri-implantitis besproken. Er 
wordt stilgestaan bij de sleutelrol die het systemische gebruik van antibiotica kan spelen bij 
de behandeling van deze ziekten en bij vragen die betrekking hebben op de optimalisatie 
van het gebruik van systemische antibiotica bij de behandeling van genoemde 
aandoeningen. 
 
In Hoofdstuk 2 wordt de in vitro antibioticum gevoeligheid van Streptococcus constellatus 
en Streptococcus intermedius onderzocht. Deze gram-positieve parodontale bacteriële 
ziekteverwekkers zijn geassocieerd met refractaire parodontitis. De in vitro gevoeligheid 
voor amoxicilline, azitromycine, clindamycine, ciprofloxacine, doxycycline en metro-
nidazol werd onderzocht in klinische subgingivale isolaten afkomstig van patiënten met 
chronische parodontitis. Met behulp van de E-test techniek werd de minimaal remmende 
concentratie (MIC) vastgesteld.  Breekpunt concentraties werden berekend aan de hand van 
de gegevens van de Clinical and Laboratory Standards Institute (CLSI) en de European 
Committee on Antimicrobial Susceptibility Testing (EUCAST). Clindamycine bleek het 
meest werkzame antibioticum tegen S. constellatus (MIC90 = 0,25 mg/L), amoxicilline 
bleek het meest werkzame antibioticum tegen S. intermedius (MIC90 = 0,125 mg/L). 30% 
van de S. constellatus en S. intermedius klinische isolaten bleken resistent te zijn voor 
doxycycline, 98% was matig gevoelig voor ciprofloxacine en 90% was resistent voor 
metronidazol bij een concentratie van 16 mg/L. De conclusie van dit onderzoek is dat de 
variabele antibioticumgevoeligheid spectra van subgingivale S. constellatus en S. 
intermedius de keuze van een effectieve antibioticum behandeling in patiënten die positief 
zijn voor deze pathogenen kan bemoeilijken. Daarom kan microbiologische analyse en het 
vaststellen van de antibioticumgevoeligheid bijzonder nuttig zijn bij de behandeling van 
refractaire parodontitis in patiënten met subgingivale S. constellatus en S. intermedia. 
 




Enterococcus faecalis (n=47, USA patiënten) onderzocht. Deze opportunistische, gram-
positieve ziekteverwekker kan worden gevonden bij parodontitis patiënten die onvoldoende 
reageren op mechanische parodontale behandeling. De microdilutie methode werd gebruikt 
om de gevoeligheid voor ampicilline, amoxicilline, ciprofloxacine, clindamycine, 
erytromycine, teicoplanine, tetracycline-HCl, vancomycine, gentamicine en streptomycine 
vast te stellen. Daarnaast werd de resistentie voor metronidazol bij een concentratie van 4 
mg/L gemeten met behulp van de agar-dilutie methode. CLSI criteria werden gebruikt voor 
het vast stellen van breekpuntconcentraties. De klinische subgingivale E. faecalis isolaten 
lieten een aanzienlijke in vitro resistentie zien tegen tetracycline (53,2% resistent), 
erytromycine (80,8% resistent of verminderd gevoelig), clindamycine (100% voor 2 mg/L) 
en metronidazol (100% voor 4 mg/L). Subgingivale E. faecalis bleek veelal gevoelig voor 
ciprofloxacine (89,4% gevoelig; 10,6% matig gevoelig) en 100% gevoelig voor 
ampicilline, amoxicilline/clavulanaat, vancomycine en teicoplanine. Op basis van deze 
bevindingen kan worden geconcludeerd dat patiënten met hoge subgingivale aantallen E. 
faecalis mogelijk baat hebben bij een systemische behandeling met ampicilline, 
amoxicilline/clavulaanzuur, of ciprofloxacine, en dat systemische tetracycline, 
erytromycine, clindamycine en metronidazol waarschijnlijk ineffectieve middelen zijn bij 
de behandeling van een subgingivale infectie met deze pathogeen. 
 
In hoofdstuk 4 LV GH EDFWHULsOH ȕ-lactamase productie in de subgingivale microflora van 
patiënten met chronische parodontitis onderzocht. Dit enzym is in staat om de amide 
YHUELQGLQJ LQ ȕ-lactam antibiotica te hydrolyseren waardoor het antibioticum 
farmacologisch niet lDQJHUZHUN]DDPLV'H]Hȕ-lactamase productie werd onderzocht door 
subgingivale plaquemonsters van een grote groep patiënten (n=564) te inoculeren op 
verrijkte Brucella agar platen waaraan amoxicilline, en op platen waaraan amoxicilline en 
clavulaanzuur (eHQ ȕ-ODFWDPDVH UHPPHU ZHUG WRHJHYRHJG ȕ-lactamase-producerende 
bacteriën groeien op het medium waaraan amoxicilline is toegevoegd maar worden geremd 
RSKHWPHGLXPPHW DPR[LFLOOLQH HQ FODYXODDQ]XXU ,QYDQGHSDWLsQWHQZHUGHQȕ-
lactamase-producerende subgingivale bacteriën gevonden. Het meest frequent werd deze 
eigenschap aangetroffen bij Prevotella intermedia/nigrescens, andere Prevotella species en 
bij Fusobacterium nucleatum 7HYHQV ZHUG YDVWJHVWHOG GDW  YDQ GH JHYRQGHQ ȕ-
lactamase-producerende bacteriesoorten gevoelig was voor 4 mg/L metronidazol. Deze 
EHYLQGLQJHQ VXJJHUHUHQ GDW GH HIIHFWLYLWHLW YDQ HHQ PRQRWKHUDSLH PHW HHQ ȕ-lactam 
antibioticum als ondersteuning van een parodontale behandeling beperkt is. Echter, de grote 
gevoeligheid van de ȕ-lactamase-producerende bacteriesoorten voor metronidazol lijkt een 
EHODQJULMNH EHVFKHUPHQGH IDFWRU GLHZHOOLFKW DIEUDDN YDQ DPR[LFLOOLQH GRRU ȕ-lactamase-
producerende bacteriesoorten voorkomt wanneer parodontitis wordt behandeld met de 
combinatie van metronidazol en amoxicilline. 
 
In Hoofdstuk 5 is het voorkomen van in vitro antibioticum resistentie van geselecteerde 
subgingivale parodontale pathogenen in chronische parodontitis patiënten onderzocht in 
400 Amerikaanse patiënten. Subgingivale plaquemonsters uit diepe, ontstoken parodontale 
pockets werden geënt op primaire isolatie media waaraan breekpunt concentraties van 
amoxicilline (8 mg/L), clindamycine (4 mg/L), doxycycline (4 mg/L), en metronidazol (16 
mg/L) werden toegevoegd. Op deze wijze werd de resistentie van een geselecteerd aantal 
paropathogene bacteriën vastgesteld. Daarnaast werd de gevoeligheid van geïsoleerde 
gram-negatieve staafvormige enterobacteriën en Pseudomonas species voor ciprofloxacine 
onderzocht met behulp van de disc diffusie methode. In 74,2% van de chronische 
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parodontitis patiënten werd tenminste één paropathogene species gevonden die resistent 
was voor tenminste één van de onderzochte antibiotica. P. intermedia/nigrescens, S. 
constellatus of Aggregatibacter actinomycetemcomitans bleken resistent voor doxycycline, 
amoxicilline, metronidazol of clindamycine in resp. 55%. 43,3%, 30,3% en 26,5% van de 
chronische parodontitis patiënten. In 15% van de onderzochte patiënten werden pathogenen 
gevonden die resistent waren voor zowel amoxicilline als metronidazol. Dit betrof veelal S. 
constellatus of ciprofloxacine-gevoelige enterobacteriën of Pseudomonas species. Deze 
bevindingen laten zien dat chronische parodontitis patiënten in de Verenigde Staten 
subgingivaal frequent gekoloniseerd zijn met paropathogenen die resistent zijn voor 
therapeutische antibioticumconcentraties. Tevens werd aangetoond dat er een grote variatie 
bestaat in antibioticumresistentie bij paropathogene bacteriesoorten. Deze nieuwe 
informatie is van belang voor clinici die empirisch een antibioticum therapie kiezen bij de 
behandeling van chronische parodontitis. Er lijkt hier een belangrijke rol weggelegd voor 
microbiologische analyse van de subgingivale plaque en antibioticumgevoeligheid 
onderzoek bij het maken van een keuze voor een systemische parodontale antibioticum 
therapie.  
 
In Hoofdstuk 6 is de resistentie van een aantal geselecteerde paropathogene bacteriën 
onderzocht voor therapeutische concentraties van spiramycine (een macrolide 
antibioticum), amoxicilline en metronidazol. Subgingivale plaquemonsters van chronische 
parodontitis patiënten (n=37) werden geënt op primaire isolatie media waaraan breekpunt 
concentraties spiramycine ( 4 mg/L), amoxicilline (8 mg/L) en metronidazol (16 mg/L) 
werden toegevoegd. Testresultaten werden post-hoc gecombineerd voor spiramycine en 
metronidazol en voor metronidazol en amoxicilline om zo het aantal en het percentage 
paropathogenen bacteriesoorten vast te stellen dat resistent is voor een of beide 
antibioticum combinaties. Geselecteerde paropathogenen waren resistent voor spiramycine, 
amoxicilline of metronidazol in respectievelijk 48,7%, 62,2% en 27% van de chronische 
parodontitis patiënten. Spiramycine resistentie werd het meest frequent gevonden in 
Fusobacterium nucleatum (44,4% van de positieve patiënten) maar ook in lage frequentie 
(< 10% van de patiënten) in Prevotella intermedia/nigrescens, Parvimonas micra, 
Streptococcus constellatus, Streptococcus intermedius, Porphyromonas gingivalis en 
Tannerella forsythia. In één patiënt werd een S. constellatus en een S. intermedius 
gevonden die resistent waren voor zowel spiramycine als metronidazol. In een andere 
patiënt werd  een S. constellatus stam gevonden die resistent was voor metronidazol en 
amoxiccilline. In ongeveer 50% van de onderzochte chronische parodontitis patiënten werd 
een spiramycine resistente paropathogeen gevonden, in veel gevallen betrof het F. 
nucleatum. Deze bevindingen laten zien dat spiramycine als systemische monotherapie van 
beperkte betekenis is voor de behandeling van parodontitis. Echter, de in vitro gevoeligheid 
van paropathogenen, met uitzondering van A. actinomycetemcomitans, duiden op een 
mogelijke toepassing van de combinatie van spiramycine en metronidazol in patiënten met 
HHQRYHUJHYRHOLJKHLGYRRUDPR[LFLOOLQHRIDQGHUHȕ-lactam antibiotica.  
 
In Hoofdstuk 7 is het voorkomen van antibioticum resistentie bestudeerd van bacteriën die 
betrokken zijn bij peri-implantitis. Submucosale monsters van 160 implantaten met peri-
implantitis afkomstig uit 120 patiënten werden gekweekt op primaire isolatie media 
waaraan doxycycline (4 mg/L), amoxicilline (8 mg/L), metronidazol (16 mg/L) en 
clindamycine (4 mg/L) was toegevoegd. Gram-negatieve staafvormige enterobacteriën en 




van de disc diffusie test methode. Test resultaten voor metronidazol en amoxicilline werden 
post-hoc gecombineerd om bacteriesoorten die resistent waren voor beide antibiotica te 
identificeren. In 71,7% van de patiënten werden pathogenen gevonden die resistent waren 
voor één of meerdere van de geteste antibiotica. Kweekbare submucosale pathogenen, 
veelal  Prevotella intermedia/nigrescens of Streptococcus constellatus, bleken in vitro 
resistent voor clindamycine, amoxicilline, doxycycline of metronidazol in respectievelijk 
46,7%, 39,2%, 25% en 21,7% van de peri-implantitis patiënten. In 6,7% van de patiënten 
werden pathogenen gevonden die resistent waren voor zowel metronidazol als amoxicilline. 
Dit betrof Streptococcus constellatus of ciprofloxacine-gevoelige gram negatieve 
staafvormige enterobacteriën of Pseudomonas species. De resultaten laten zien dat 
patiënten met peri-implantitis frequent submucosale pathogenen hebben die resistent zijn 
voor therapeutische concentraties van clindamycine, amoxicilline, doxycycline of 
metronidazol maar slechts zelden voor de combinatie van metronidazol en amoxicilline. 
Antibioticum gevoeligheid bepaling van submucosale pathogenen kan behulpzaam zijn bij 
de keuze van een antimicrobiële therapie bij de behandeling van patiënten met peri-
implantitis.  
 
In Hoofdstuk 8 worden de gevonden onderzoeksresultaten besproken in het licht van 
parodontale diagnostiek en toepassing in de parodontale en de implantologische praktijk. 
Op basis van de bevindingen in dit proefschrift wordt geconcludeerd dat microbiologisch 
onderzoek, in casu de evaluatie van de antibioticumgevoeligheid van specifieke 
pathogenen, een extra mogelijkheid biedt aan clinici bij hun keuze voor de selectie van een 
systemische antimicrobiële therapie bij de behandeling van parodontitis en peri-implantitis. 
Hiermee kan de kans op therapie falen worden verkleind. In dit hoofdstuk worden klinische 
aanbevelingen gedaan hoe deze nieuwe informatie in de praktijk kan worden 
geïmplementeerd. Tevens worden voorstellen gedaan voor toekomstig onderzoek op het 
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